

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 November 2002 (07.11.2002)

PCT

(10) International Publication Number
WO 02/088387 A2

- (51) International Patent Classification⁷: C12Q 1/68
- (21) International Application Number: PCT/GB02/01861
- (22) International Filing Date: 22 April 2002 (22.04.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0110501.4 30 April 2001 (30.04.2001) GB
- (71) Applicant (*for all designated States except US*): THE SECRETARY OF STATE FOR DEFENCE [GB/GB]; DSTL, Porton Down, Salisbury, Wiltshire SP4 0JQ (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): CLARK, Duncan, Roy [GB/GB]; GeneSys Limited, Suite 5, St. Albans House, 40 Lynchford Road, Farnborough, Hants GU14 6EF (GB). VINCENT, Suzanne, Patricia [GB/GB]; GeneSys Limited, Suite 5, St Albans House, 40 Lynchford Road, Farnborough, Hants GU14 6EF (GB).
- (74) Agent: GREAVES, Carol, Pauline; Greaves Brewster, 24A Woodborough Road, Winscombe, North Somerset BS25 1AD (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: AMPLIFICATION PROCESS

(57) Abstract: A method for conducting a nucleic acid amplification reaction, said method comprising forming an amplification reaction mixture in the presence of sufficient of a pyrophosphate salt to prevent primer extension taking place, digesting said pyrophosphate salt with a pyrophosphatase enzyme (PPase), and subjecting said reaction mixture to conditions such that an amplification reaction may proceed. This can be used as a "hot start" amplification. Particular novel pyrophosphatase enzymes for use in the method are also described and claimed.

BEST AVAILABLE COPY

Amplification Process

The present invention relates to processes for carrying out reactions in which nucleic acids are amplified, to means of
5 controlling these reactions and kits and reagents, in particular enzymes, used for conducting them.

Amplification reactions such as the polymerase chain reaction (PCR) are very well known and widely used in the fields of
10 biotechnological research, as well as in diagnostics and detection.

PCR is a procedure for generating large quantities of a particular nucleic acid sequence, in particular a DNA sequence,
15 and is based upon DNA's characteristics of base pairing and precise copying of complementary DNA strands. Typical PCR involves a cycling process of three basic steps.

Denaturation : A mixture containing the PCR reagents (including the nucleic acid to be copied, which may be DNA or RNA (the
20 template), the individual nucleotide bases (A,T,G,C), suitable primers and polymerase enzyme) are heated to a predetermined temperature to separate the two strands of the target DNA.

Annealing : The mixture is then cooled to another predetermined temperature and the primers locate their complementary
25 sequences on the DNA strands and bind to them.

Extension : The mixture is heated again to a further predetermined temperature. The polymerase enzyme (acting as a catalyst) joins the individual nucleotide bases to the end of the primer to form a new strand of DNA which is complementary
30 to the sequence of the target DNA, the two strands being bound together.

Such reactions rely on the sequence of steps occurring in a very precise order and at the precise temperature required for the operation of that step. A problem arises when reagents are
35 mixed together, even for short periods of time, at different

temperatures, for example prior to the start of the reaction. Primers may interact with nucleic acid template, resulting in primer extension of the template. This can lead to a reduction in the overall yield of the desired product as well as the
5 production of non-specific products.


Various means of overcoming this problem have been proposed previously. For example, initial attempts to overcome the problem used a wax barrier to separate the various PCR reagents
10 from each other in a test tube (see for example USP 5,565,339). The wax melted as the reaction mixture was heated to the initial denaturation temperature, allowing the reagents to mix together at the last possible moment, so that the possibility of side-reactions was minimised. Such reactions are known as
15 "Hot Start" reactions.

Other chemical methods for achieving the suppression of side-reactions have been attempted. For example, US Patent No. 5,677,152 describes a method in which the DNA polymerase is
20 chemically modified to ensure that it only becomes active at elevated temperatures. In order to carry out this method however, it is necessary to incubate the reaction mixture at high temperatures for some time in order to generate active enzyme. Such delays, whilst not significant in some instances,
25 can be detrimental where the results of PCR are required rapidly. For many applications of the PCR technique it is desirable to complete the sequence of cycles in the minimum possible time. In particular for example where respiratory air or fluids or foods for human and animal stock consumption are
30 suspected of contamination rapid diagnostic methods may save considerable money if not health, even lives.


In other methods, a monoclonal antibody to *Thermus aquaticus* (Taq) DNA polymerase such as the anti-Taq DNA polymerase antibody available from Sigma, is introduced into the reaction
35 mixture. The antibody binds to the enzyme, so as to inactivate it, at ambient temperature. However, the antibody denatures and dissociates from the enzyme at elevated temperatures used

during the amplification cycles and so the enzyme becomes active. The method however does not appear to eliminate non-specific side-products in some cases.

- 5 Primer extension of a template during a PCR reaction can be represented as:



where dNTP is a deoxyribonucleic acid triphosphates, dNMP is the corresponding deoxyribonucleic acid monophosphate and PPi is an inorganic pyrophosphate. This reaction may also be represented as



The presence of increased levels of PPi, for example in a DNA sequencing reaction is known to force the reaction shown above in reverse. This is known as pyrophosphorolysis and it is a
20 recognised problem in DNA sequencing at 70°C using thermostable DNA polymerases. It has been overcome through the addition of a thermostable PPase to the DNA polymerase formulation used in DNA sequencing.

- 25 The applicants have found that this reaction can form the basis of an advantageous amplification reaction in which the production of non-specific products may be minimised.

According to the present invention there is provided a method
30 for conducting a nucleic acid amplification reaction, said method comprising forming an amplification reaction mixture in the presence of sufficient of a pyrophosphate salt to prevent primer extension taking place, enzymatically digesting said pyrophosphate, and subjecting said reaction mixture to
35 conditions such that an amplification reaction may proceed.

Using the method of the invention, accurate amplification reactions, which may be carried out rapidly and with good specificity, can be carried out. It therefore represents a good alternative to existing "Hot Start" amplification technologies.

The initial amplification reaction mixture used in the method of the invention is broadly speaking, a conventional mixture, such as that used in the PCR reaction, to which pyrophosphate salt is added. Thus it will generally comprise: i) a sample which contains or is suspected of containing a target nucleic acid sequence, (ii) at least one primer which hybridises to an end region of said target sequence, iii) a source of magnesium ions, (iv) nucleotide or nucleoside bases which constitute the target sequence (i.e. A, T, C, G and/or U in the case of DNA amplification or A,U,C and G in the case of RNA amplification), and (v) a DNA polymerase which is thermostable at the temperatures at which the amplification reaction is effected. It will also comprise a buffer, as necessary in order to effect the reaction, as is known in the art.

In particular (iv) will comprise nucleotides A, T, G and C in respect of DNA amplification and nucleosides A, U, C and G in respect of RNA amplification.

Other combinations may be used however, where other primer based amplifications reactions such as reverse transcriptase PCR (RT-PCR) are being conducted.

In addition, the reagents may include labelled probes or primers, and/or other labelling means such as intercalating dyes such as Sybr Green, Sybr Gold, ethidium bromide etc. or combinations of these, which might allow the application to be monitored, without the need to examine the product on a gel subsequently. The nature of these depends upon the type of assay being undertaken. Generic intercalator methods use intercalating dyes to monitor the increase in double stranded

DNA which occurs during an amplification process. These are only quasi-strand-specific and therefore other labels are required where strand specific detection is required.

5 Strand specific methods utilise additional nucleic acid reaction components to monitor the progress of amplification reactions. These methods often use fluorescence energy transfer (FET) as the basis of detection. One or more nucleic acid probes are labelled with fluorescent molecules, one of
10 which is able to act as an energy donor and the other of which is an energy acceptor molecule. These are sometimes known as a reporter molecule and a quencher molecule respectively. The donor molecule is excited with a specific wavelength of light which falls within its excitation spectrum and subsequently it
15 will emit light within its fluorescence emission wavelength. The acceptor molecule is also excited at this wavelength by accepting energy from the donor molecule by a variety of distance-dependent energy transfer mechanisms. A specific example of fluorescence energy transfer which can occur is
20 Fluorescence Resonance Energy Transfer or "FRET". Generally, the acceptor molecule accepts the emission energy of the donor molecule when they are in close proximity (e.g. on the same, or a neighbouring molecule). The basis of fluorescence energy transfer detection is to monitor the changes at donor and
25 acceptor emission wavelengths.

There are two commonly used types of FET or FRET probes, those using hydrolysis of nucleic acid probes to separate donor from acceptor, and those using hybridisation to alter the spatial
30 relationship of donor and acceptor molecules.

Hydrolysis probes are commercially available as TaqMan™ probes. These consist of DNA oligonucleotides that are labelled with donor and acceptor molecules. The probes are
35 designed to bind to a specific region on one strand of a PCR product.

Following annealing of the PCR primer to this strand, *Taq* enzyme extends the DNA with 5' to 3' polymerase activity. *Taq* enzyme also exhibits 5' to 3' exonuclease activity. *TaqMan*TM probes are protected at the 3' end by phosphorylation to
5 prevent them from priming *Taq* extension. If the *TaqMan*TM probe is hybridised to the product strand, an extending *Taq* molecule may also hydrolyse the probe, liberating the donor from acceptor as the basis of detection. The signal in this instance is cumulative, the concentration of free donor and
10 acceptor molecules increasing with each cycle of the amplification reaction.

US Patent No. 5,491,063 describes a method for in-solution quenching of fluorescently labelled probes which relies on
15 modification of the signal from a labelled single stranded oligonucleotide by a DNA binding agent. The difference in this signal which occurs as a result of a reduced chain length of the probe following probe cleavage (hydrolysis) during a polymerase chain reaction is suggested for providing a means
20 for detecting the presence of a target nucleic acid.

Hybridisation probes are available in a number of forms. Molecular beacons are oligonucleotides that have complementary 5' and 3' sequences such that they form hairpin loops.
25 Terminal fluorescent labels are in close proximity for FRET to occur when the hairpin structure is formed. Following hybridisation of molecular beacons to a complementary sequence the fluorescent labels are separated, so FRET does not occur, and this forms the basis of detection.

30 Pairs of labelled oligonucleotides may also be used. These hybridise in close proximity on a PCR product strand bringing donor and acceptor molecules together so that FRET can occur. Enhanced FRET is the basis of detection. Variants of this type
35 include using a labelled amplification primer with a single adjacent probe.

US Patent No. 4,868,103 describes in general terms, a FRET system for detecting the presence of an analyte, which utilises an intercalating dye as the donor molecule. The process does not involve an amplification stage.

5

Other examples of assays which utilise FET or FRET detection are described in WO 99/28500, which utilises a combination of an intercalating dye and a single labelled probe as a signalling system, WO 99/28501 which utilises a combination of a labelled primer and an enzyme to generate a detectable
10 fluorescent signal, and WO 99/42611 which uses a combination of an intercalating dye and a fluorescently labelled nucleotide as the basis of the signal. Yet further assays which utilise complex primers including labels and chemical blocking agents
15 and which are complementary are described for example in WO 99/66071.

Reaction mixtures used in the method of the invention may include any of the labelling reagents necessary to conduct
20 assays as described above. In particular, such reaction mixtures may advantageously be used in genotyping and, more especially, in SNP evaluation. In these instances, the method of the present invention is used in combination with dual Taqman™ probes, one specific for the basic sequence and one
25 specific for the mutant. Each probe preferably contains a different flurophore and therefore different signals are generated depending on the amount of the various forms of the gene present. A single signal is generated from a homozygote and a mixed signal is generated from a heterozygote.

30

Examples of suitable DNA polymerases which may be used in the context of the invention are thermostable polymerases such as *Thermus aquaticus* polymerase (Taq), *Thermus thermophilus* polymerase (Tth), *Thermus species NH* polymerase (TspNH),
35 *Thermus brockianus* polymerase (Tbr) (all obtainable for example from GeneSys Limited, Farnborough, U.K.), *Pyrococcus furiosus* polymerase (Pfu) (obtainable from Stratagene), 9°N7 exo-DNA

polymerase, and *Thermococcus litoralis* DNA polymerase (obtainable from New England Biolabs as VENT™ DNA polymerase).

The pyrophosphate used in the method of the invention may be
5 any soluble pyrophosphate including soluble metal and non-metal (e.g. ammonium salts). Such compounds are often generically known as "inorganic pyrophosphate" or PPI and this nomenclature is used in the present application. In particular, the pyrophosphate will be an alkali metal pyrophosphate, such as
10 sodium or potassium pyrophosphates including disodium pyrophosphate ($\text{Na}_2\text{H}_2\text{P}_2\text{O}_7$), anhydrous tetrasodium pyrophosphate ($\text{Na}_4\text{P}_2\text{O}_7$), tetrasodium pyrophosphate decahydrate ($\text{Na}_4\text{P}_2\text{O}_7 \cdot 10\text{H}_2\text{O}$) and tetrapotassium pyrophosphate (anhydrous). Other soluble pyrophosphates which may be used include iron pyrophosphates
15 such as ferric pyrophosphate ($\text{Fe}_4(\text{P}_2\text{O}_7)_3$), and soluble ammonium salts such as anhydrous tributylammonium pyrophosphate. Other soluble pyrophosphates are available from commercial sources.

A preferred inorganic pyrophosphate is tetrasodium
20 pyrophosphate of formula $\text{Na}_4\text{P}_2\text{O}_7$.

The concentration of pyrophosphate used in the reaction mixture should be sufficient to prevent primer extension taking place. This will depend to a large extent upon the particular nature
25 and concentration of the sequences being amplified, the primers and the polymerase enzymes being used, as well as their concentrations, and may be determined in any particular case by routine methods.

30 The reaction mixture formed initially suitably contains pyrophosphate at a concentration of at least 0.5mM, suitably at a concentration of least 1mM, for example from 1-10mM and preferably from 1-5mM.

35 Enzymatic digestion of the inorganic pyrophosphate is suitably effected immediately prior to or during first phase of the amplification reaction. This may be achieved by addition of an

pyrophosphatase enzyme (PPase) (which may be known as an inorganic pyrophosphatase enzyme - PPIase) immediately prior to the start of the amplification reaction.

- 5 Preferably, however, the enzymatic digestion is effected using a thermostable PPase, which is active at elevated temperatures, for example at temperatures in excess of 50°C. Preferably the enzyme is only significantly active at these elevated temperatures. This means that the PPase may be included in the
10 reaction mixture on formation, but it will not or not significantly digest the inhibitory pyrophosphate at ambient temperature. It will only become properly active when the reaction mixture is heated as will be necessary for example during the initial denaturation phase of a PCR reaction.
15 However, a short preliminary incubation at elevated temperature, for example at from 50 to 100°C, and, preferably, at from 80 to 95°C, may be carried out.

- Examples of thermostable PPase include *Sulfolobus acidicaldarius*
20 pyrophosphatase, (Sac PPase - Meyer et al. Archives of Biochem. and Biophys. (1995) 319, 1, 149-156) obtainable from GeneSys Limited, Farnborough UK., or *Thermococcus litoralis* pyrophosphatase, available from New England Biolabs (Catalogue nos #M0296S and #M0296L). Preferably the thermostable PPase is
25 *Aeropyrum pernix* inorganic pyrophosphatase obtainable from Genesys Limited, Farnborough UK.

- Aeropyrum pernix* K1, the first strictly aerobic
hyperthermophilic archaeon, was isolated in 1993 from a coastal
30 solfataric thermal vent at Kodakara-Jima Island, Japan, (Sako et al, Int. J. Syst. Bacteriol. 46 (1996): 1070-1077. It is deposited in the Japan Collection of Microorganisms, JCM 9820.

- The applicants have for the first time isolated a thermostable
35 PPase from *Aeropyrum pernix* and this forms a further aspect of the present invention. The genomic sequence comprising this pyrophosphatase is shown in SEQ ID NO. 1 and the corresponding

amino acid sequence is shown in SEQ ID NO. 2 (Figure 11 hereinafter). In particular the enzyme of the invention has the amino acid sequence as shown as SEQ ID NO 25, which is encoded by the region of SEQ ID NO 1 shown in bold type in Figure 11, and represented also as SEQ ID NO 26.

The present invention, therefore, includes a polynucleotide comprising SEQ ID NO 26 and variants or fragments thereof. For example, the invention provides a polynucleotide of SEQ ID NO 1.

The present invention further includes an amino acid sequence comprising SEQ ID NO 25 and variants or fragments thereof. For example, the amino acid sequence may comprise SEQ ID NO 2.

The term "fragment thereof" as used herein in relation to a polynucleotide sequence refers to any portion of the given polynucleotide sequence which has the same activity as the complete polynucleotide sequence. Fragments will suitably comprise at least 300 and preferably at least 450 consecutive bases from the basic sequence.

The term "variant thereof" in relation to a polynucleotide sequences means any substitution of, variation of, modification of, replacement of deletion of, or the addition of one or more nucleic acid(s) from or to a polynucleotide sequence providing the resultant protein sequence encoded by the polynucleotide exhibits the same properties as the protein encoded by the basic sequence. The term therefore includes allelic variants and also includes a polynucleotide which substantially hybridises to the polynucleotide sequence of the present invention. Preferably, such hybridisation occurs at, or between low and high stringency conditions. In general terms, low stringency conditions can be defined as 3 x SSC at about ambient temperature to about 55°C and high stringency condition as 0.1 x SSC at about 65°C. SSC is the name of the buffer of 0.15M NaCl. 0.015M tri-sodium citrate. 3 x SSC is three times

as strong as SSC and so on.

Typically, variants have 62% or more of the nucleotides in common with the polynucleotide sequence of the present invention, more typically 65%, preferably 70%, even more preferably 80% or 85% and, especially preferred are 90%, 95%, 98% or 99% or more identity.

When comparing nucleic acid sequences for the purposes of determining the degree of identity, programs such as BESTFIT and GAP (both from Wisconsin Genetics Computer Group (GCG) software package). BESTFIT, for example, compares two sequences and produces an optimal alignment of the most similar segments. GAP enables sequences to be aligned along their whole length and finds the optimal alignment by inserting spaces in either sequence as appropriate. Suitably, in the context of the present invention when discussing identity of nucleic acid sequences, the comparison is made by alignment of the sequences along their whole length.

The term "fragment thereof" as used herein in relation to an amino acid sequence refers to any portion of the given amino acid sequence which has the same activity as the complete amino acid sequence. Fragments will suitably comprise at least 100 and preferably at least 150 consecutive amino acids from the basic sequence.

The term "variant thereof" as used herein in relation to an amino acid sequence means sequences of amino acids which differ from the base sequence from which they are derived in that one or more amino acids within the sequence are substituted for other amino acids. Amino acid substitutions may be regarded as "conservative" where an amino acid is replaced with a different amino acid with broadly similar properties. Non-conservative substitutions are where amino acids are replaced with amino acids of a different type. Broadly speaking, fewer non-conservative substitutions will be possible without altering

the biological activity of the polypeptide. Suitably variants will be at least 60% identical, preferably at least 75% identical, and more preferably at least 90% identical to the base sequence.

5

Homology in this instance can be judged for example using the algorithm of Lipman-Pearson, with Ktuple:2; gap penalty:4, Gap Length Penalty:12, standard PAM scoring matrix (Lipman, D.J. and Pearson, W.R., Rapid and Sensitive Protein Similarity Searches, *Science*, 1985, vol. 227, 1435-1441).

10

Preferably, the polynucleotide of the present invention comprises SEQ ID NO 26 and sequences having greater than 62% identity thereto.

15

These enzymes may be obtained from the natural source, or may be expressed in recombinant host cells, such as *E. coli* cells, using conventional methods.

20 Removal of pyrophosphate for example, at $>50^{\circ}\text{C}$ by the action of a thermostable pyrophosphatase enzyme (PPase) then allows primer extension (and therefore amplification) to proceed as normal. During this process, 1mole of pyrophosphate is converted to 2moles of inorganic phosphate (Pi), which does not
25 interfere with the amplification reaction.

The amount of pyrophosphatase included should be sufficient to digest excess pyrophosphate salt present in the reaction mixture. Generally speaking, this will be greater than the
30 amounts of these enzymes used conventionally in an equivalent cycle reaction to prevent pyrophosphorolysis, for example some 5 fold more. The precise amounts will depend upon various factors including the particular enzyme being used, the concentration of the pyrophosphate etc. Typically, PPase and
35 particularly thermostable PPase enzymes will be included in the amplification reaction mixture at concentrations of at least 0.04 units per 50 μL PCR reaction mixture, preferably at least

0.08 units per 50 μ L PCR reaction mixture and more preferably from about 0.2-10 units per 50 μ L PCR reaction mixture. In this case, one unit is defined as the amount of enzyme catalysing the conversion of 1 μ mol pyrophosphate into 2 μ mol orthophosphate in one minute at 75°C under the following reaction conditions:
5 1mM K₄P₂O₇, 2mM MgCl₂, 50mM Tris-HCl, pH 9.0 (25°C).

Enzymes used in the method of the invention can result in rapid removal of inorganic pyrophosphate, depending upon the
10 temperature being used. Generally complete removal can be achieved in less than 5 minutes, more often, in less than 2 minutes and as little as 15 seconds if required.

Once the inorganic pyrophosphate has been enzymatically removed
15 from the reaction mixture, the amplification reaction can proceed, for example using a conventional thermal cycling procedure.

The mechanism by which the method of the invention achieves the
20 desired result is not clear. It is probable that the presence of excess pyrophosphate inhibits the primer extension reaction. There appears, however, to be no noticeable decrease in PCR sensitivity or product yield.

25 The method of the invention can be conducted in any conventional apparatus for conducting application reactions. These include conventional block heating devices as described for example in EP-A-0810030 and supplied by The Perkin-Elmer Corporation, or rapid hot air thermal cyclers such as the
30 RapidCycler™ and LightCycler™ from Idaho Technologies Inc. or other types of thermal cycler such as those described in WO98/24548.

According to a further aspect, the invention provides a kit for
35 conducting an amplification reaction; said kit comprising an inorganic pyrophosphate, an inorganic pyrophosphatase enzyme,

and optionally one or more reagents required for use in an amplification reaction. The inorganic pyrophosphate is suitably present in a sufficient amount to inhibit an amplification reaction, as described above. Preferably the
5 amount of inorganic pyrophosphatase enzyme present in the kit is sufficient to digest all of the said inorganic pyrophosphate.

The one or more reagents include any one of reagents (ii) to
10 (v) listed above, and may also include buffers. Particular examples of inorganic pyrophosphatase enzymes are thermostable inorganic pyrophosphatase enzymes as described above.

In particular, the kits may suitably comprise as an optional
15 additional reagent, one or more primers required to conduct amplification of a particular target DNA sequence, for example, a sequence, which is diagnostic of a particular disease condition or the presence of a particular pathogen in a sample. The methods may also be used in the detection of polymorphisms
20 or allelic variations in genetic analysis.

Furthermore, the kits may comprise one or more labelled reagents such as intercalating dyes, or fluorescently labelled probes, primers or nucleotides, which may be useful in
25 detecting or monitoring the amplification reaction in situ.

In a further aspect, the invention provides the use of an inorganic pyrophosphate as described above, in a method for carrying out amplification reactions as described above.
30 Preferably, the inorganic pyrophosphatase enzyme is from *Aeropyrum pernix*.

Finally, in yet a further aspect, the invention provides the use of an inorganic pyrophosphatase enzyme as described above,
35 in a method for carrying out amplification reactions as described above.

The invention will now be particularly described by way of example with reference to the accompanying diagrammatic drawings in which

5 Figure 1 shows the results of conducting a PCR in the presence of various amounts of PPI where PPI is tetrasodium pyrophosphate;

Figure 2. shows the effect of increasing $MgCl_2$ in the absence
10 and presence of 3mM PPI;

Figure 3 shows the results obtained using the method of the invention and conventional PCR reaction;

15 Figure 4 shows the results obtained using the method of the invention in an assay compared to a conventional PCR assay;

Figure 5 shows the results of an experiment to test the storage stability of PCR reaction mixtures used in the method of the
20 invention, as compared to conventional mixtures;

Figure 6 shows the results of the use of a different PPase in the method of the invention;

25 Figure 7a and 7b and Figures 8a and 8b show the results of PCR experiments using the method of the invention and a variety of different DNA polymerases;

Figure 9 shows the results of an experiment comparing a
30 conventional "Hot Start" PCR with the method of the invention;

Figure 10 shows the results obtained by carrying out a similar assay but using an alternative conventional PCR;

35 Figure 11 shows the genomic sequence of *Aeropyrum pernix* shown as SEQ ID NO. 1 (Referenced as NC 000854 in GenBank BA000002),

the corresponding amino acid sequence SEQ ID NO.2 and the sequence of the enzyme (SEQ ID NO 25);

Figure 12 shows an alignment of different PPase sequences (SEQ ID NOS 2 to 9), including the protein sequence of *Aeropyrum pernix* shown as SEQ ID NO. 2;

Figure 13 shows the 686 base pair PCR product (SEQ ID NO 10) produced during isolation of the pyrophosphatase enzyme from *Aeropyrum pernix*;

Figure 14 shows the polylinker sequence (SEQ ID NO 11) used in the isolation of the pyrophosphatase from *Aeropyrum pernix*;

Figure 15 shows the sequence of the pTTQ18NHK vector (SEQ ID NO 12) used in the isolation of the pyrophosphatase from *Aeropyrum pernix*;

Figure 16 shows the sequence (Z = stop) of the pTTQ18NHK vector including the PPase sequence used in the isolation of the pyrophosphatase from *Aeropyrum pernix* (SEQ ID NO 13); and

Figure 17 shows the results of the method of the invention using the inorganic pyrophosphatase from *Aeropyrum pernix*.

Example 1

Effect of PPI on PCR

Using *Taq* DNA polymerase, a standard 500bp lambda template PCR using the following reagents, was conducted in the presence of differing quantities of the inorganic pyrophosphate, tetrasodium pyrophosphate decahydrate (PPI).

Reagent	Volume	Final concn.
10 x Reaction Buffer	5µl	1x
25mM MgCl ₂	3µl	1.5mM
5mM dNTPs	2µl	200µM

17

5' primer (10pm/ μ l)	5 μ l	1 μ M
3' primer (10pm/ μ l)	5 μ l	1 μ M
Template	1ng	Lambda DNA
DNA polymerase (5u/ μ l)	0.25	1.25u
Water to Total volume	50.0 μ l	

Lambda 500bp Primer sequences

5' Primer GAT GAG TTC GTG TCC GTA CAA CTG G (SEQ ID NO 14)
 5 3' Primer GGT TAT CGA AAT CAG CCA CAG CGC C (SEQ ID NO 15)

1 x Reaction Buffer: 10mM Tris. pH 8.0, 50mM KCl.

PCR conditions for the assay were as follows:

- i) 94°C 3.00 min
- 10 ii) 20 cycles of
 - 94°C for 10 secs
 - 50°C for 10 secs
 - 72°C for 30 secs
- iii) 72°C for 7 mins
- iv) 25°C hold,

15

The PPI was added such that the final concentration in the reaction mixture was 0, 1, 2, 3, 4 and 5mM. The results are shown in Figure 1. In this Figure, the lanes correspond to the following concentrations of PPI

20

Lanes

1 + 2 0 PPI
 3 + 4 1mM PPI
 5 + 6 2mM PPI
 7 + 8 3mM PPI
 9 + 10 4mM PPI
 11 5mM PPI

At all levels of PPI tested, no PCR product was produced.

Example 2Effect of increasing magnesium ion concentration

Mg binds to PPI and therefore it is possible that the observations of Example 1 are due to chelation of Mg by excess PPI. This would lead to insufficient Mg being present to allow primer extension to proceed. In order to eliminate this possibility, the procedure of Example 1 with 3mM PPI was repeated in the presence of various concentrations of magnesium ions.

10

The results are shown in Figure 2. In that Figure the lanes represent the following reactions:

Lanes

1 + 2	1.5mM MgCl ₂
3 + 4	5mM MgCl ₂
5 + 6	7.5mM MgCl ₂
7 + 8	10mM MgCl ₂
9 + 10	1.5mM MgCl ₂ + 3mM PPI
11 + 12	5mM MgCl ₂ + 3mM PPI
13 + 14	7.5mM MgCl ₂ + 3mM PPI
15	10mM MgCl ₂ + 3mM PPI

The results show that the addition of Mg⁺⁺ up to 10mM final concentration (1.5mM is standard in a PCR) does not allow PCR to occur, suggesting that it is the PPI which is blocking primer extension.

Example 3PCR reactions in the presence of Ppi and PPase

The 500bp lambda PCR of Example 1 was repeated, but this time, 0.2u of *Sulfolobus acidocaldarius* PPase (Sac PPase) was included in reactions containing pyrophosphate (PPI). Incubating the reaction at 95°C for 5 mins in the presence of 0.2u of Sac PPase was sufficient to destroy the pyrophosphate so that the PCR reaction could proceed.

The results are shown in Figure 3 where the lanes represent the following reactions:

Lanes**Top Row**

1 + 2	1mM PPI + 0.2u PPase
3 + 4	2mM PPI + 0.2u PPase
5 + 6	3mM PPI + 0.2u PPase
7 + 8	4mM PPI + 0.2u PPase
9 + 10	5mM PPI + 0.2u PPase

Bottom Row

1 + 2	1mM PPI
3 + 4	2mM PPI
5 + 6	3mM PPI
7 + 8	4mM PPI
9 + 10	5mM PPI
11 + 12	0mM PPI

5

A comparable level of PCR product was generated when compared to the reaction without both PPI and PPase.

10 The example was repeated using concentrations of PPI of less than 1mM. Results (not shown) indicated that 0.4mM PPI did not completely suppress the PCR, but no PCR occurred at concentrations of 0.6mM

Example 415 PCR Assay

The method of the invention was then applied to an assay system that requires a "HotStart" reaction in order to generate a PCR product of the correct size.

20 The assay is based around the amplification of a 321bp fragment of the human angiotensin gene. It has been recognised that the assay will only generate the correct amplification product in

the presence of betaine (EP-A-0962526 - see in particular Example 8).

Without betaine a HotStart DNA polymerase generates few non-specific amplification products or no products at all whereas a non-HotStart DNA polymerase PCR generates a large number of non-specific amplification products.

The PCR conditions used in the Angiotensin assay can be summarised as follows.

Reagent	Volume	Final concn.
10x Reaction Buffer	5 μ l	1x
25mM MgCl ₂	3 μ l	1.5mM
5mM dNTPs	2 μ l	200 μ M
5' primer (100 μ M)	0.25	0.5/ μ M
3' primer (100 μ M)	0.25	0.5/ μ M
Template 100ng/ μ l	50ng	Human xsomal DNA
5M Betaine	10.0	1M
DNA polymerase (5u/ μ l)	0.25	1.25u
Water to Total volume	50.0 μ l	

Angiotensin primer sequences

15 5' Primer GCA ACG CCC CTC ACT ATA AA (SEQ ID NO 16)
 3' Primer GCA CCC CGC CCT TGA AGT CC (SEQ ID NO 17)

1 x Reaction Buffer: 10mM Tris. pH 8.0, 50mM KCl.

PCR conditions for the assay were as follows:

- 20 i) 95°C 2.00 min or less
 ii) 35 cycles of 95°C for 15 secs
 50°C for 30 secs
 72°C for 30 secs
 iii) 72°C for 7 mins
 25 iv) 25°C hold

The reaction was conducted using a PE9700 Instrument in the presence of 3mM PPI and 0.2u PPase as described in Example 3.

The results are shown in Figure 4 in which the Lanes shown
5 represent the following reactions.

Lanes

- 1 Standard *Taq* polymerase PCR - without betaine - lots of false priming
- 2 Standard *Taq* polymerase PCR - with betaine - bright band is correct product - with some false priming
- 3 Standard *Taq* polymerase PCR - without betaine but plus 3mM PPI and 0.2u Sac PPase - No false priming at all - 5mins denaturation at 95°C
- 4 Standard *Taq* polymerase PCR - with betaine but plus 3mM PPI and 0.2u Sac PPase - only correct product - 5mins denaturation at 95°C
- 5 + 6 As per 3 but only 2 mins denaturation at 95°C
- 7 + 8 As per 4 but only 2 mins denaturation at 95°C

It is clear that using the method of the invention, an effective "HotStart" reaction is achieved. A clear single
10 product band was obtained using PPI and Sac PPase in the presence of betaine. In addition, no false priming was seen, even in the absence of betaine.

Example 5

15 Effects of Storage at Ambient Temperature

The effect of leaving a PCR mixture containing 0.2u Sac PPase and 3mM PPI at room temperature 20°C for various lengths of time prior to conducting the Angiotensin assay, was investigated. Although Sac PPase is a thermostable enzyme, it
20 was possible that there would be a small level of enzyme activity at ambient temperatures. This might lead to insufficient PPI in the reaction to inhibit/stop the DNA polymerase leading to primer extension and lack of "HotStart" functionality.

The method of Example 4 was repeated but the reaction mixtures were stored at ambient temperature for various lengths of time up to 2 hours prior to conducting the assay.

5 The results are shown in Figure 5 in which:

The Top Row - shows the results of a conventional *Taq* polymerase PCR of angiotensin (with and without betaine present) following incubation of reagents at room temperature
10 for the time shown; and

The Bottom Row shows the results of a similar set of assays in accordance with the method of the invention where, in all cases, the assay mix contained 3mM PPi and 0.2u PPase per 50µl
15 PCR.

Lanes	Presence of betaine	Time at 22°C (Room Temp)
1 + 2	-	0
3 + 4	+	0
5 + 6	-	30 mins
7 + 8	+	30 mins
9 + 10	-	60 mins
11 + 12	+	60 mins
13 + 14	-	120 mins
15 + 16	+	120 mins

Even after two hours, assay conducted in accordance with the present invention functioned as expected, suggesting there is
20 insufficient ambient temperature digestion of the PPi by the Sac PPase.

The result shown in Figure 5 showed that a 2 hour incubation of the PCR mix at room temperature, prior to PCR, had no effect on
25 the specificity providing PPi and Sac PPase was used.

Example 6Use of other thermostable PPase enzymes in the method of the invention

The assay described in Example 4 was repeated alongside a similar reaction using a different commercially available thermostable PPase (with different unit definition of activity) in place of Sac PPase. The results are shown in Figure 6 in which the lanes represent the following reactions:

Lanes

- | | |
|---------|--|
| 1 + 2 | Standard <i>Taq</i> polymerase PCR - without betaine |
| 3 + 4 | Standard <i>Taq</i> polymerase PCR - with betaine |
| 5 + 6 | Standard <i>Taq</i> polymerase PCR - without betaine but plus 3mM PPI and 0.2u Sac PPase |
| 7 + 8 | Standard <i>Taq</i> polymerase PCR - with betaine plus 3mM PPI and 0.2u Sac PPase |
| 9 + 10 | Standard <i>Taq</i> polymerase PCR - without betaine but plus 3mM PPI and 10u* <i>Thermococcus litoralis</i> PPase |
| 11 + 12 | Standard <i>Taq</i> polymerase PCR - with betaine plus 3mM PPI and 10u* <i>Thermococcus litoralis</i> PPase |

10

* Units used in this case were as supplied by the manufacturer and are defined as the amount of enzyme that will generate 40nmoles of phosphate per minute under standard reaction conditions (10 minute reaction at 75°C in 50mM Tricine [pH 8.5], 1mM MgCl₂, 0.32mM PPI, reaction volume of 0.5ml).

15

Thermococcus litoralis PPase (available from New England Biolabs) appears to have the same effect as Sac PPase in this assay.

20

Example 7Use of different thermostable DNA polymerases in the method of the invention

A variety of thermostable DNA polymerases were employed in the method of the invention and some comparative assays. These included several non-proofreading *Thermus* sp. DNA polymerases,

25

proof-reading hyperthermophilic archaeal DNA polymerases and mixes of non-proofreading and proofreading DNA polymerases.

They were all tested using the 500bp lambda PCR as described in Example 1 (Figure 7a and 7b), and several using the Angiotensin assay as described in Example 4 (Figure 8a and 8b).

Details of the assay conditions are summarised as follows:

10 Figure 7a - *Thermus* DNA polymerases

Lanes

Top Row

1 + 2	<i>Taq</i> polymerase 0mM PPi and no PPase
3 + 4	<i>Taq</i> polymerase 3mM PPi and no PPase
5 + 6	<i>Taq</i> polymerase 3mM PPi and 0.2u Sac PPase
7 + 8	<i>Tbr</i> polymerase 0mM PPi and no PPase
9 + 10	<i>Tbr</i> polymerase 3mM PPi and no PPase
11 + 12	<i>Tbr</i> polymerase 3mM PPi and 0.2u Sac PPase

Bottom Row

1 + 2	<i>Tth</i> polymerase 0mM PPi and no PPase
3 + 4	<i>Tth</i> polymerase 3mM PPi and no PPase
5 + 6	<i>Tth</i> polymerase 3mM PPi and 0.2u Sac PPase
7 + 8	<i>TspNH</i> polymerase 0mM PPi and no PPase
9 + 10	<i>TspNH</i> polymerase 3mM PPi and no PPase
11 + 12	<i>TspNH</i> polymerase 3mM PPi and 0.2u Sac PPase

Figure 7b - Archaeal Proof-reading DNA polymerases

Lanes**Top Row**

- 1 + 2 *Pfu* polymerase 0mM PPi and no PPase
- 3 + 4 *Pfu* polymerase 3mM PPi and no PPase
- 5 + 6 *Pfu* polymerase 3mM PPi and 0.2u Sac PPase
- 7 + 8 9°N *exo-* polymerase 0mM PPi and no PPase
- 9 + 10 9°N *exo-* polymerase 3mM PPi and no PPase
- 11 + 12 9°N *exo-* polymerase 3mM PPi and 0.2u Sac PPase

Bottom Row

- 1 + 2 VENT polymerase 0mM PPi and no PPase
- 3 + 4 VENT polymerase 3mM PPi and no PPase
- 5 + 6 VENT polymerase 3mM PPi and 0.2u Sac PPase

Fig 8a Angiotensin assay without PPi and without Sac PPase
(with and without Betaine)**Lanes**

- 1 + 2 *Taq* polymerase without betaine
- 3 + 4 *Taq* polymerase with betaine
- 5 + 6 *Accurase* polymerase without betaine
- 7 + 8 *Accurase* polymerase with betaine
- 9 + 10 *Tbr* polymerase without betaine
- 11 + 12 *Tbr* polymerase with betaine
- 13 + 14 *Tth* polymerase without betaine
- 15 + 16 *Tth* polymerase with betaine

Fig 8b Angiotensin assay with PPi and Sac PPase (with and
5 without Betaine)

Control Lanes 1-4 (Top Row) and 12-16 (Bottom Row)

Lanes

Top Row

- 1 + 2 *Taq* polymerase without betaine but plus 3mM PPi -
 No Sac PPase
- 3 + 4 *Taq* polymerase with betaine but plus 3mM PPi - -
 No Sac PPase

All below with 3mM PPi and 0.2u Sac PPase

- 5 + 6 *Taq* polymerase without betaine
- 7 + 8 *Taq* polymerase with betaine
- 9 + 10 *Accurase* polymerase without betaine
- 11 + 12 *Accurase* polymerase with betaine
- 13 + 14 *Tbr* polymerase without betaine
- 15 + 16 *Tbr* polymerase with betaine

Bottom Row

All below with 3mM PPi and 0.2u Sac PPase

- 1 + 2 *Tth* polymerase without betaine
- 3 + 4 *Tth* polymerase with betaine
- 5 + 6 *TspNH* polymerase without betaine
- 7 + 8 *TspNH* polymerase with betaine
- 9 + 10 *Pfu* polymerase without betaine
- 11 + 12 *Pfu* polymerase with betaine
- 13 + 14 *Taq* polymerase control without betaine and no PPi
 or PPase
- 15 + 16 *Taq* polymerase control with betaine and no PPi or
 PPase

All DNA polymerases tested were inhibited by PPi and that inhibition could be overcome with Sac PPase.

Comparative Example 8Comparison of method of invention with conventional "Hotstart" methodologies

We have some initial results (Figure 9 and 10) that show that a chemically modified Taq polymerase (modified as described in US Patent No 5,677,152) does generate some false PCR products in the absence of betaine but gives the correct product in the presence of betaine.

10 Figure 9 Angiotensin assay

Lanes

1 + 2	Taq polymerase without betaine
3 + 4	Taq polymerase with betaine
5 + 6	Chemically modified Taq without betaine
7 + 8	Chemically modified Taq with betaine
9 + 10	Method of the invention (3mM PPi and 2u Sac PPase) without betaine
11 + 12	Method of the invention (3mM PPi and 2u Sac PPase) with betaine

It appears that under these circumstances, the chemically modified enzyme is inactive until it has a 10 min activation at 95°C. Without this preliminary incubation, negligible PCR product was generated. The apparent false priming and generation of wrong PCR products in the absence of betaine is difficult to explain however, since the chemically modified Taq is inactive at room temperature.

20

Figure 10 Angiotensin assay with Taq and anti-Taq antibody

Lanes

1 + 2	Anti-Taq antibody plus Taq polymerase without betaine
3 + 4	Anti-Taq antibody plus Taq polymerase with betaine

In an anti-Taq DNA polymerase antibody mediated HotStart, a substantial number of false products are generated in the

25

absence of betaine (similar to a standard *Taq* polymerase PCR without betaine) and a minor false product is also generated along with the correct product in the presence of betaine.

- 5 The method of the invention appears to give a rapid PCR reaction which is more specific than both of these commercial HotStart methodologies.

Example 9

10 Isolation of inorganic pyrophosphatase from *Aeropyrum pernix*

Aeropyrum pernix was obtained from the J.C.M. culture collection. The inorganic pyrophosphatase enzyme was cloned, expressed and purified.

15 Cloning and expression of inorganic pyrophosphatase from

A. pernix

The genome sequence comprising the pyrophosphatase gene of *Aeropyrum pernix* is shown in Figure 11. The primers used were designed from the genome sequence of *Aeropyrum pernix*. These
20 are shown below as 5' to 3' with the restriction sites shown in bold.

Upper primer, introducing the <i>Nde</i> I site: (SEQ ID NO 18)

TGCATG CATATG ACAGGCTGTCTGAAAATTG
--

Lower primer, introducing the <i>Hind</i> III site: (SEQ ID NO 19)
--

TAAGTGTA AAGCTT GACTGTGGGGCGGTGAAAG
--

- Aligning the putative sequence from the genome with other
25 pyrophosphates genes suggested that a later ATG should be the start methionine and not the one shown in the databank (shown in italics in SEQ ID NO.1 in Figure 11) and that the amino acid sequence of the enzyme is, in fact, as shown in SEQ ID NO 25. Primers were therefore designed corresponding to the later
30 methionine (shown in bold in SEQ ID NO.1 in Figure 11).

A PCR was run using 100ng of the *Aeropyrum pernix* DNA in a 100µl volume with 50pM of the above primers. 20 cycles were run with 55°C annealing and a 45 second extension time.

5

Initial hold of 3mins at 94°C

20 Cycles of 94°C, 10 secs, 55°C, 10 secs, 68°C, 45 secs.

10

Final hold of 72°C 7 minutes

PCR conditions.

50pM Upper Primer (5'..TGCATGCATATGACAGGCTGTCTGAAAATTG..3'-SEQ ID NO:18)

15

50pM Lower Primer (5'..TAAGTGTAAGCTTGACTGTGGGGCGGTGAAAG..3' - SEQ ID NO 19)

1.5mM MgCl₂

1.25u Accurase DNA polymerase (Cat. No. AC001, GeneSys Ltd.)

75mM Tris, pH 8.8

20

20mM Ammonium sulphate

0.1% (w/v) Tween20

100ng *Aeropyrum pernix* genomic DNA

The PCR product was 686 base pairs long as shown in Figure 13:

25

The PCR product was Prepanol™ (Cat. No. P001, GeneSys Ltd.) precipitated following the manufacturers recommended conditions and finally re-suspended in 10mM Tris, 0.1mM EDTA.

The PCR product was digested with restriction enzymes Nde I and

30

Hind III, phenol extracted, precipitated with ethanol and re-suspended in 10mM Tris, 0.1mM EDTA.

pTTQ18NHK vector (shown in Figure 15) had also been digested

with Nde I and Hind III, phenol extracted, ethanol precipitated

35

and re-suspended in 10mM Tris, 0.1mM EDTA.

100ng cut PCR sequence was ligated with 1µg of cut pTTQ18NHK

vector (see Figure 16) in a total volume of 10 μ l, overnight at 16°C in 1x NEB ligation buffer using 200u of New England Biolabs T4 DNA ligase. The plasmid vector was pTTQ18NHK, a modified form of vector pTTQ18 (Stark MJ, Gene, 1987; 51(2-3):255-67) containing a kanamycin antibiotic gene inserted at the unique Eco0109 I restriction enzyme site and a replacement polylinker (see Figure 14) inserted between the EcoR I site and Hind III site of the original vector.

20 μ l of water was added and the reaction heated to 70°C for 20mins. 1/10 volume of 3M sodium acetate, pH 5.2 and 2 volumes of ethanol added. It was mixed and stored at -20°C for 1 hour. After microfuging at 10,000g for 10mins, the supernatant was removed from the pelleted DNA and the DNA re-suspended in 5 μ l water.

0.5 μ l was electroporated into *E.coli* TOP10F' cells and following 1 hour recovery at 37°C, aliquots of the cells were plated on Kanamycin Luria Broth agar plates. The plates were incubated at 37°C overnight.

Colonies were gridded in duplicate on both a fresh Kanamycin Luria Broth agar plate and a Kanamycin Luria Broth agar plate prepared by addition of 1 μ l of 20mg/ml XGAL and 1 μ l of 0.5M IPTG per ml of agar gel (KIX plate).

Following overnight incubation at 37°C, white colonies on the KIX plate were screened by PCR with M13 forward and reverse primers for the presence of an insert corresponding to the *Aeropyrum pernix* PCR product.

9 colonies containing a 701bp product were grown up in 20ml LB plus 100 μ g/ml Kanamycin to an OD600 of 1.0 then expression was induced by addition of IPTG to 0.5mM final. Cells were grown for a further 4hours and then the cells harvested and stored frozen at -20°C.

Cells were lysed by addition of 0.5ml 50mM Tris-HCl, pH 7.9, 50mM dextrose, 1mM EDTA and 0.5ml 10mM Tris-HCl, pH7.9, 50mM KCl, 1mM EDTA, 0.5% v/v Tween 20, 0.5% (v/v) Nonidet-P40 and incubation at 80°C for 15 minutes.

5

Following centrifugation at 10,000g for 10 minutes at room temperature, an aliquot from each lysed cells were analysed by SDS polyacrylamide gel electrophoresis using a 12% gel. The gel was run then stained with Coomassie blue R250. All samples
10 showed a band of approx 23kDa, which corresponds to the size of the putative PPase.

The same samples were then assayed for PPase activity at 75°C using the colorimetric assay of Jukka K. Heinonen, Reijo J.
15 Lahti. (1981) Analytical Biochemistry, Vol.113, pp313-317.

All samples showed as positive, confirming that the expressed protein possessed thermophilic inorganic pyrophosphatase activity.

20

The first clone was subsequently used for larger scale production of the protein.

Purification of the Pyrophosphatase

25 This clone was in 24 litres of LB. Once the OD₆₀₀ reached approximately 1.5, the culture was induced with 0.5mM IPTG and left to grow for a further 4 hours. The cells were then harvested and the cell pellet lysed. The expressed enzyme was purified by standard column chromatography on phenyl-sepharose
30 CL4B (Amersham Pharmacia Biotech), hydroxylapatite (Bio-rad Laboratories) and Hi-Performance Q Sepharose (Amersham Pharmacia Biotech), finally being stored at -20°C in 20mM Tris-HCl, pH 8.0, 100mM NaCl, 0.5% (v/v) Tween 20, 0.5% (v/v) Nonidet P40, 0.1mM EDTA, 1mM dithiothreitol and 50% glycerol.

35

Example 10PCR Assay using the *A. pernix* inorganic pyrophosphatase enzyme

The method of the present invention was carried out using the *A. pernix* inorganic pyrophosphatase enzyme. The assay is based
5 around the amplification of the human B-actin gene.

In this assay, a kit was used which was obtained from from Eurogentec S.A., Parc Scientifique du Sart-Tilman, rue Bois Saint-Jean 14, 4102 SERAING, Belgium (Cat. No. RT-QP73-05).
10 The standard Taq polymerase was substituted for the HotStart Taq polymerase provided with the kit.

PCR reaction mixture

1x Reaction Buffer
15 200µM, dATP, dCTP, dGTP and 400µM dUTP
0.025u/µl unmodified Taq polymerase
0.002u/µl *Aeropyrum pernix* inorganic pyrophosphatase
0.3µM 5' Primer (5' GAC TCG TCA TAC TCC TGC TTG CT 3' - SEQ ID NO 22)
20 0.3µM 3' Primer (5' CAT TGC CGA CAG GAT GCA GAA 3' - SEQ ID NO 23)
0.15µM Taqman probe (FAM-ATCCACATCTGCTGGAAGGTGGACAGT-TAMRA - SEQ ID NO 24)
5mM MgCl₂
25 2mM NaPPi
Passive Reference
1 in 4 dilutions of Human genomic DNA starting with 7.5ng (2500 copies)

30 Cycling conditions

Initial denaturation of 94°C 3 minutes

40 cycles of 94°C, 15 seconds and 60°C, 60 seconds
35

The results are shown in Figure 19.

In conclusion we believe that using the method of the invention, by using pyrophosphate to inhibit a PCR and then removing that inhibition, for example at 80°C-95°C through the use of a thermostable PPase, behaves in the same manner as
5 HotStart PCR but at a rapid rate with the additional benefit of increased specificity.

All references mentioned in the above specification are herein incorporated by reference. Other modifications of the present
10 invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with the specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such
15 specific embodiments. Indeed, various modifications of the described modes for carrying out the invention, which are obvious to those skilled in the art, are intended to be within the scope of the following claims.

Claims

1. A method for conducting a nucleic acid amplification reaction, said method comprising forming an amplification
5 reaction mixture in the presence of sufficient of a pyrophosphate salt to prevent primer extension taking place, digesting said pyrophosphate salt with a pyrophosphatase enzyme (PPase), and subjecting said reaction mixture to conditions such that an amplification reaction may proceed.
10
2. A method according to claim 1 wherein the amplification reaction is a polymerase chain reaction (PCR) and the reaction mixture contains reagents suitable for conducting such a reaction.
15
3. A method according to claim 1 or claim 2 wherein the reaction mixture contains a DNA polymerase which is selected from *Thermus aquaticus* polymerase (Taq), *Thermus thermophilus* polymerase (Tth), *Thermus species NH* polymerase (TspNH),
20 *Thermus brockianus* polymerase (Tbr), *Pyrococcus furiosus* polymerase (Pfu), 9°N7 exo-DNA polymerase, and *Thermococcus literalis* DNA polymerase.
4. A method according to any one of the preceding claims
25 wherein the inorganic pyrophosphate is an alkali earth metal pyrophosphate.
5. A method according to claim 4 wherein the inorganic pyrophosphate is tetrasodium pyrophosphate of formula $\text{Na}_4\text{P}_2\text{O}_7$.
30
6. A method according to any one of the preceding claims wherein the pyrophosphate is present in the reaction mixture at a concentration of at least 0.5mM.
- 35 7. A method according to claim 6 wherein the pyrophosphate is present at a concentration of from 1-10mM.

8. A method according to any one of the preceding claims wherein the said digestion is effected using a thermostable PPase.

5

9. A method according to claim 8 wherein the thermostable PPase is *Sulfolbus acidicaldarius* inorganic pyrophosphatase, (Sac PPase), *thermococcus litoralis* inorganic pyrophosphatase or *Aeropyrum pernix* inorganic pyrophosphatase.

10

10. A method according to claim 8 or claim 9 wherein the thermostable PPase is added to the reaction mixture on formation thereof.

15

11. A method according to claim 10 which includes a incubation step prior to the amplification reaction at elevated temperature in order to allow the PPase to digest inorganic pyrophosphate present.

20

12. A method according to any one of the preceding claims wherein the PPase is added to the reaction mixture at a concentration of at least 0.04u per 50µL PCR reaction mixture.

13. A method according to claim 12 wherein the PPase is added to the reaction mixture at a concentration of 0.08u per 50µL PCR reaction mixture.

25

14. A method according to claim 12 or claim 13 wherein the PPase is added to the reaction mixture at a concentration of from 0.2-10u per 50µL PCR reaction mixture.

30

15. A kit for conducting an amplification reaction, said kit comprising a pyrophosphate salt, an pyrophosphatase enzyme, and optionally one or more reagents required for use in an amplification reaction.

35

16. A kit according to claim 15 which further comprises one or more primers necessary to carry out amplification of a particular target nucleic acid.
- 5 17. A kit according to claim 15 or claim 16 which further includes one or more fluorescently labelled reagents.
- 10 18. A kit according to claim 17 wherein the fluorescently labelled reagents are selected from one or more of an intercalating dye, a fluorescently labelled probe, a fluorescently labelled primer or a fluorescently labelled nucleotide.
- 15 19. The use of a pyrophosphate salt in a method for carrying out amplification reactions as claimed in any one of claims 1 to 14.
- 20 20. The use of a pyrophosphatase enzyme in a method for carrying out amplification reactions as claimed in any one of claims 1 to 14.
21. A pyrophosphatase enzyme isolated from *Aeropyrum pernix*.
- 25 22. A pyrophosphatase enzyme encoded by the polynucleotide sequence as shown in SEQ ID NO.26 or a variant or fragment thereof.
- 30 23. A pyrophosphatase enzyme comprising the amino acid sequence as shown in SEQ ID NO. 25 or a variant or fragment thereof.
24. An isolated polynucleotide which encodes an enzyme according to claim 22 or claim 23.
- 35 25. The use of a pyrophosphatase enzyme as claimed in any one of claims 21 to 23 in a method for carrying out amplification reactions as claimed in any one of claims 1 to 14.

26. A method for conducting an amplification reaction substantially as herein before described with reference to the Examples.



FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7a



FIGURE 7b



FIGURE 8a



FIGURE 8b



FIGURE 9



FIGURE 10

Figure 11

Aeropyrum pernix sequence

MWTILPSKTGFVNSLSFITRLAKLSVRRVHAMTGCLKIGPGDEAPDVVNVVIEIPMN
 SSVKYEFDKEACIVKVDRFLYTSMVYPFNYGFIPGTLEEDGDPVDVLVISREPVAPG
 SLIEAVPVAVLDMEEDEEPPDSKVAVPKAKLDPLFASYKDVGDIPDALKSKIKHFFE
 HYKELEPGKWVRVTGWRPAADAKEIIRRAIERYKGA

(SEQ ID NO 2)

SEQ ID NO 1

1066801 taatcctaata tgcgtttatg tggacgatcc ttcccagcaa aaccgggttt gttaacagcc
 1066861 ttagctttat aactcgacta gccaaactat cgggttagacg ggtgcatgca atgacaggct
 1066921 gtotgaaat tggtoctgga gatgaggctc cagatgttgt gaatgtcgtt atagagatac
 1066981 ctatgaacag ttctgttaag tacgagttcg acaaggaggc gtgtattgtt aaggttgata
 1067041 ggttccttta caccagcatg gtctaccct tcaactacgg gtctatacca ggcaototag
 1067101 agggagacgg agatcctgtt gacgttctag ttattagcgg ggagcccgtt gctcccggt
 1067161 cgcttataga ggctgtgccc gtggcgtgt tagacatgga ggacgaggag ggtccggaca
 1067221 gcaagggtgt tgcgtacccc aaggccaagc tggacccct attcgccagc tataaggacg
 1067281 ttgacgacat acctgatgcc ctgaaatcca agataaagca cttcttcgag cactataagg
 1067341 agctggagcc tggaaagtgg gttagagtga ctggatggag gcctgctgcc gatgcgaagg
 1067401 agattataag gagggctata gagaggtata agggggcgtg atgaggcctt aacggctcac
 1067461 gttttctggg agagtgtcgc acctttgagg gcgatcacc tgcacagcgt gcgtgtgctt
 1067521 ttgtctatga ttatggctac agttcttcta gccgcttca ccgccccac agtcaataca
 1067581 cttacaccta gaggttctgc gctgtatgct gtggatgtag ttgtagtaga cgccagcaca
 1067641 ggatctgccc tgggggtctc ccggtttgtc gtatccgctt acagaggggg ggtcggggat
 1067701 gtgggtgtta tctactcttc gggggtctca gtatcagggt ctagtctgga aaggctgctg

MTGCLKIGPGDEAPDVVNVVIEIPMNSSSVKYEFDKEACIVKVDRFLYTSMVYPFNYG
 FIPGTLEEDGDPVDVLVISREPVAPGSLIEAVPVAVLDMEEDEEPPDSKVAVPKAKL
 DPLFASYKDVGDIPDALKSKIKHFFEHYKELEPGKWVRVTGWRPAADAKEIIRRAIE
 RYKGA (SEQ ID NO 25)

SEQ ID NO 26

atgacaggct gtctgaaat tggtoctgga gatgaggctc cagatgttgt
 gaatgtcgtt atagagatac ctatgaacag ttctgttaag tacgagttcg
 acaaggaggc gtgtattgtt aaggttgata ggttccttta caccagcatg
 gtctaccct tcaactacgg gtctatacca ggacactctag agggagacgg
 agatcctgtt gacgttctag ttattagcgg ggagcccgtt gctcccggt
 cgcttataga ggctgtgccc gtggcgtgt tagacatgga ggacgaggag
 ggtccggaca gcaagggtgt tgcgtacccc aaggccaagc tggacccct
 attcgccagc tataaggacg ttggcgacat acctgatgcc ctgaaatcca
 agataaagca cttcttcgag cactataagg agctggagcc tggaaagtgg
 gttagagtga ctggatggag gcctgctgcc gatgcgaagg agattataag
 gagggctata gagaggtata agggggcgtg a

Figure 13

686bp PCR product. (SEQ ID NO 10)

RE sites in bold, PPase gene in italics, primer sites underlined

TGCATGCATATGACAGGCTGTCTGAAAATTGGTCCTGGAGATGAGGCTCCAGATGTTGTGAATGTCGTT
ATAGAGATACCTATGAACAGTTCTGTTAAGTACGAGTTCGACAAGGAGGCGTGATTGTTAAGGTTGAT
AGGTTCCCTTTACACCAGCATGGTCTACCCCTTCAACTACGGGTTTCATACCAGGCACTCTAGAGGAGGAC
GGAGATCCTGTTGACGTTCTAGTTATTAGCCGGGAGCCCGTTGCTCCCGGCTCGCTTATAGAGGCTGTG
CCCGTGGCCGTGTTAGACATGGAGGACGAGGAGGGTCCGGACAGCAAGGTTGTTGCCGTACCCAGGCC
AAGCTGGACCCCTATTGCGCCAGCTATAAGGACGTTGGCGACATACCTGATGCCCTGAAATCCAAGATA
AAGCACTTCTTCGAGCACTATAAGGAGCTGGAGCCTGGAAAGTGGGTTAGAGTGACTGGATGGAGGCCT
GCTGCCGATGCGAAGGAGATTATAAGGAGGGCTATAGAGAGGTATAAGGGGGCGTGATGAGGGCTTAAC
GGCTCACGTTTTCTGGGAGAGTGTCGCACCTTTGAGGGCGATCACCTCGCCAGCGTGCGTGTGCTTTT
GTCTATGATTATGGCTACAGTTCTTCTAGCCGCTTTCACCGCCCCACAGTCAAGCTTACACTTA

Figure 14

Modified polylinker sequence of pTTQ18N HK from initial ATG to the *Nde* I site and then the *Hind* III site (SEQ ID NO 11)

Met *Nde* I
ATGCACCACCACCACCACCATATGGGCATGCTGAATTCGAGCTCGGTACCCGGGGATCCTCTAGAGTCG
ACCTGCAGGCATGCAAGCTT
Hind III

Figure 15

pTTQ18NHK sequence (SEQ ID NO 12)

>PTTQ18NHK Sequence
GAACTGGATCTCAACAGCGGTAAAGATCCTTGAGAGTTTTCGCCCCGAAGAAGCTTTTCCA 60
ATGATGAGCACTTTAAAGTTCTGCTATGTGGCGGGTATTATCCCGTATTGACGCCGGG 120
CAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACC 180
GTCACAGAAAAGCATCTTACCGATGGCATGACAGTAAGAGAATTATGCAGTGTCTGCCATA 240
ACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAG 300
CTAACCGCTTTTTCGACAAACATGGGGGATCATGTAACCTCGCTTGATCGTTGGGAACCG 360
GAGCTGAATGAAGCCATACCAACGACGAGCGTGACACCACGATGCCGTGTAGCAATGGCA 420
ACAACGTTGCCCAAACTATTAACCTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTA 480
ATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCCTTCTGCGCTCGGCCCTTCCGGCT 540
GGCTGGTTTATGTGATAAATCTGGAGCCCGTGAGCGTGGGTCTCGCGGTATCATTGCA 600
GCATCGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGAGTCAG 660
GCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGTGTCTCACTGATTAGCAT 720
TGGTAACCTGTGAGCAAGTTTACTCATATATACTTTAGATTGATTTAAACTTCATTTT 780
TAATTTAAAGGATCTAGGTGAAGATCCTTTTGTATAATCTCATGACCAAAATCCCTTAA 840
CGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGA 900
GATCCTTTTTTCTGCGCGTAACTGTGCTGTGCAAAACAAAACACCGCTACCAGCG 960
GTGGTTTGTTCGCCGATCAAGAGCTACCAACTCTTTTCCGAAGGTAAGTGGCTTCAG 1020
AGAGCGCAGATACCAATACTGTCTTCTAGTGTAGCGTAGTTAGGCCACCACTTCAAG 1080
AACTCTGTAGCACCCTTACATACCTCGCTCTGTCTAATCTGTGTACAGTGGCTGTCTGC 1140
AGTGGCGATAJ JTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGCG 1200
CAGCGGTTCGGCTGTAACGGGGGTTCTGTGCACACGCCAGCTTGGAGCGAACGACCTAC 1260
ACCGAACTGAGATACCTACAGCGTGAGCATTGAGAAAGCGCCACGCTTCCCGAAGGGAGA 1320
AAGCGGACAGGATCCGGTAAGCGCGGCGGGTCGGAACAGGAGAGCGCACGAGGGAGCTT 1380
CCAGGGGGAACGCTGTGTATCTTTATAGTCTGTGCGGTTTCGCCACCTCTGACTTTGAG 1440
CGTCGATTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAACACGCCAGCAACGCG 1500
GCTTTTTCAGGTTTCTGCGCTTTTGGCTTTTGTCTGCTGCTGCTGCTGCTGCTGCTGCT 1560
TCCCTGATTTCTGTGATAACCGTATTACCGCTTTGAGTGTGCTGATACCGCTCGCCGC 1620
AGCCGAACGACCGGACCGCGAGTCAGTGTGAGCGAGGAGCGGAAGAGCGCCCAATACGC 1680
AAACCGCTCTTCCCGCGCGTTGGCCGATTCTAATGCAGAAATTAATCTCATGTTTGA 1740
CAGCTTATCATGACTGCACGCTGACCAATGCTTCTGGCGTCAGGACGCTACCGAAGC 1800
TGTGTAAGGCTGTGACGCTGTAATCACTGCATAATCTGTGCTGCTCAAGCGCAGCT 1860
CCGTTCTGGATAATGTTTTTTCGCCCGACATCATAACGGTTCTGGCAAAATATCTGAAAT 1920
GAGCTGTGACAAATTAATCATCGGCTGTATATGTGTGAATTTGAGCGGATAACAAAT 1980
TTCACACAGGAACACATATATGACCAACCAACCAACCAATATGGGCATGCTGAATTCGA 2040
GCTCGGTACCCGGGATCCTCTAGAGTCGACCTGCAGGATGCAAGCTTGGCACTGGCCG 2100
TCGTTTACAACTGCTGACTGGGAAACCCCTGGCGTTACCAACTTAATCGCTTGCAG 2160
CACATCCCTTTTCGCCAGCTGGCGTAATAGCGAAGAGGCGCGCACCGATCGCCCTTCCC 2220
AACAGTTGCGAGCTGAATGGCGAATGGCGCTGTGCGGTATTTCTCCTTACGCATC 2280
TGTGCGGTATTTACACCGCATAAATTCCTGTTTGGCGGATGAGAGAAGATTTTCAGC 2340
CTGATACAGATTAAATCAGAACGACGAGCGGTCTGATAAACAGAAATTTGCTGGCGGC 2400
AGTACGCGGTGGTCCCACCTGACCCATGCCGAACCTAGAACTGAAACGCGGTAGCGCC 2460
GATGGTAGTGTGGGCTCTCCCATGCGAGAGTAGGGAACCTGCCAGGCATCAATAAAACG 2520
AAGGCTCAGTCGAAAGACTGGGCCCTTTCGTTTATCTGTTGTTTGTGCGGTGAACGCTCT 2580
CCTGAGTAGGACAAATCCGCCGGGAGCGGATTGTAACGTTGCGAAGCAACGCCCGGAGG 2640
GTGGCGGCGAGACGCCGCCATAAACTGCCAGGCATCAAAATAGCAGAAAGGCCATCCT 2700
GACGGATGGCCTTTTTCGTTTCTACAACTCTTCTGTGCTCATATCTACAAGCCATCC 2760
CCCCACAGATACGGTAACTAGCCTCGTTTTCATCAGGAAAGCAGGGAATTTATGGTG 2820
CACTCTCAGTACAATCTGCTCTGATGCCGATAGTTAAGCCAGCCCCGACCCGCCAAC 2880
ACCCGCTGACGCGCCTGACGGGCTGTCTGCTCCCGCATCCGCTTACAGACAAGCTGT 2940
GACCGCTCCGGGAGCTGCATGTGTAGAGGTTTTCACCGTCATCACCGAAACGCGCGAG 3000
ACGAAAGGGCTGATTAGAAAACTCATCGAGCATCAATGAACTGCAATTTATTCATA 3060
TCAGGATTATCAATACCATATTTTGAAGAAAGCCGTTTCTGTAATGAAGGAGAACTCA 3120
CCGAGGCGAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCA 3180
ACATCAATACAACCTATTAATTTCCCTCGTCAAAATAAGGTTATCAAGTGAAGAAATCA 3240
CCATGAGTGACGACTGAATCCGGTGAGAAATGGCAAAAGNTTATGCATTTCTTCCAGACT 3300
TGTTCAACAGGCGACGCTTACGCTCGTCAATCAAACTCACTGCTCATCAACCAACCGTTA 3360
TCTATTCTGATTGCGCTGAGCGAGACGAAATACCGGATCGCTGTAAAAGGACAATTA 3420
CAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAAATTTTCA 3480
CCTGAATCAGGATATTTCTTAATACCTGGAATGCTGTTTCCCGGATCGCAGTGGTG 3540
AGTAACCATGCTATCAGGAGTACGGATAAATGCTTGTGCTCGGAAGAGGCATAAAT 3600
TCCGTGAGCCAGTTTGTCTGACCATCTCATCTGAACATCATTGGCAACGCTACCTTTG 3660
CCATGTTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCA 3720
CCTGATTGCCCGACATTTATCGCGAGCCCAATTTATACCATATAAATCAGCATCCATGTTG 3780
GAATTTAATCGCGGCTCGAGCAAGAGCTTTCCCGTTGAATATGGCTCATACACCCCTT 3840
GTATTACTGTTTATGTAAGCAGACGTTTATTTGTTATGATGATATATTTTATCTTGT 3900
GCAATGTAACATCAGGCCCTCGTGTACGCTATTTTATAGGTTAATGTCATGATAATA 3960

Figure 15 cont'd...

```

ATGTTTCTTAGACGTGAGGTTCTGTACCCGACACCATCGAATGGTGCAAAACCTTTCGC 4020
GGTATGGCATGATAGCGCCCGGAAGAGAGTCAATTCAGGGTGGTGAATGTGAAACCASTA 4080
ACGTTATACGATGTGCGCAGAGTATGCCGGTGTCTTATCAGACCGTTTCCCGCGTGGTG 4140
AACCAGGCCAGCCAGCTTCTGCGAAAAACGCGGAAAAAGTGGAGCGCGATGGCGGAG 4200
CTGAATTACATTCCCAACCGGTGGCACAACAACTGGCGGGCAACAGTCGTTGCTGATT 4260
GGCGTTGCCACCTCCAGTCTGGCCCTGCACGCGCGTCGCAAAATTGTCGCGCGATTA 4320
TCTCGCGCCGATCAACTGGGTGCCAGCGTGGTGGTGTGATGGTAGAACGAAGCGCGCTC 4380
GAAGCCTGTAAAGCGGCGGTGCACAATCTTCTCGCGCAACGCGTCAGTGGGCTGATCATT 4440
AACTATCCGCTGGATGACCAGGATGCCATTGCTGTGGAAGCTGCCTGCACATATGTTCCG 4500
GCGTTATTTCTTGATGTCTCTGACCAGACACCCATCAACAGTATTATTTCTCCCATGAA 4560
GACGGTACGCGACTGGGCGTGGAGCATCTGGTCGCATTGGGTCAACAGCAAAATCGCGCTG 4620
TTAGCGGGCCCATTAAGTTCTGTCTCGGCGCGTCTGCGTCTGGCTGGCTGGCATAAATAT 4680
CTCACTCGCAATCAAATTCAGCCGATAGCGGAACGGGAAGCGACTGGAGTGCCATGTCC 4740
GGTTTTCAACAAACCATGCAAAATGCTGAATGAGGGCATCGTTCCCACTGCGATGCTGGTT 4800
GCCAACGATCAGATGGCGCTGGGCGCAATGCGCGCCATTACCGAGTCCGGGCTGCGCGTT 4860
GGTGGGATATCTCGGTAGTGGGATACGACGATACCGAAGACAGCTCATGTTATATCCCG 4920
CCGTTAACACCATCAAACAGGATTTTCGCCTGCTGGGCAAAACGCGTGGACCGCTTG 4980
CTGCAACTCTCTCAGGGCCAGGCGGTGAAGGGCAATCAGCTGTTGCCGCTCTCACTGGTG 5040
AAAAGAAAAACCCCTGGCGCCCAATACGCAAAACCGCTCTCCCGCGCGTTGGCCGAT 5100
TCATTAAATGCAGCTGGCAGCAGGTTTCCCGACTGGAAGCGGGCAGTGAGCGCAACGC 5160
AATTAATGTAGTTAGCTCACTCATTAGGCACCCAGGCTTTACACTTTATGCTTCCGAC 5220
CTGCAAGAACCCTCAGTCAAGTGGCACTTTTCGGGAAATGTGCGCGGAACCCCTATTTG 5280
TTTATTTTCTAAATACATTCAAAATATGTATCCGCTCATGAGACAATAACCTGATAAAT 5340
GCTTCAATAATATTGAAAAAGAGAGTATGAGTATTCACATTTCGCTGTCGCCCTTAT 5400
TCCCTTTTTCGCGCATTTTGCCTTCCTGTTTTCCTCACCCAGAAACGCTGGTGAAAGT 5460
AAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACATC 5503

```

Figure 16

pTTQ18NHK sequence containing PPase (**bold**) and remainder of PCR product cloned (*italics*) (SEQ ID NO 13)




Figure 16 cont'd...

>PTTQ18NHK-PPASE SEQUENCE


GAAC TGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTGCGCCCGAAGAACGTTTTCCA 60
ATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGG 120
CAAGAGCAACTCGGTGCGCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTACCA 180
GTACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATA 240
ACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAG 300
CTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCTCGCCTTGATCGTTGGGAACCG 360
GAGCTGAATGAAGCCATACCAACGACGAGCGTGACACCAGATGCCTGTAGCAATGGCA 420
ACAACGTTGCGCAAACTATTAACCTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTA 480
ATAGACTGGATGGAGGCGGATAAAGTTGACAGGACCACTTCTGCGCTCGGCCCTTCCGGCT 540
GGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCA 600
GCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAG 660
GCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCAT 720
TGGTAACCTGTACAGCAAGTTTACTCATATATACTTTAGATTGATTTAAAACCTCATTTT 780
TAATTTAAAAGGATCTAGGTGAAGATCCTTTTGTATAATCTCATGACCAAAATCCCTTAA 840
CGTGAGTTTTCGTCCACTGAGCGTCAGACCCGTAAGAAAGATCAAAGGATCTTCTTGA 900
GATCCTTTTTTCTGCGCGTAATCTGCTGCTTGCAAAACAAAAAACCCGCTACACGCG 960
GTGTTTTGTTTGGCGGATCAAGAGCTACCAACTCTTTTCCGAAGGTAACCTGGCTTCAGC 1020
AGAGCGCAGATACCAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAG 1080
AACTCTGTAGCACCGCTACATACCTCGCTCTGCTAATCTGTTACCAGTGGCTGCTGCC 1140
AGTGGCGATAAGTCGTGCTTACCAGGTTGGACTCAAGACGATAATTACCAGGATAAGGCG 1200
CAGCGGTGGGGCTGAACGGGGGGTTCGTGCACACAGCCAGCTTGGAGCGAACGACCTAC 1260
ACCGAAGTGAATACCTACAGCGTGAGCATGAGAAAGCGCCACGCTTCCCGAAGGGAGA 1320
AAGCGGACAGGTATCCGGTAAGCGCGAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTT 1380
CCAGGGGAAACGCGTGGTATCTTTATAGTCTGTGCGGTTTTCGCCACCTCTGACTTGAG 1440
CGTCGATTTTGTGCTGCTCGTCAGGGGGCGGAGCCTATGGAATAACGCCAGCAACGCG 1500
GCCTTTTTACGGTTCCTGGCCTTTTGTGCGCTTTTGTCTACATGTTCTTTCTGCGTTA 1560
TCCCTGATTTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGC 1620
AGCGGAACGACGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGC 1680
AAACCGCCTCTCCCGCGCGTTGGCCGATTCAATTAATGCAGAAATTAATCTCATGTTTGA 1740
CAGCTTATCATCGACTGCACGCTGCACCAATGCTTCTGGCGTCAGGCAGCCATCGGAAGC 1800
TGTGGTATGGCTGTGACGCTGTAATCACTGCATAATTCGTGTGCTCAAGGCGCACTC 1860
CCGTTCTGGATAATGTTTTTGGCGCGACATCATACCGGTTCTGGCAAAATATTCTGAAAT 1920
GAGCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAAT 1980
TTCACACAGGAACACATATATGCACACCACCACCACTATGACAGGCTGTCTGAAAA 2040
TTGGTCTGGAGATGAGGCTCCAGATGTTGTGAATGTCGTTATAGAGATACCTATGAACA 2100
GTTCTGTTAAGTACGAGTTTCGACAAGAGGCGTGATTGTTAAGGTTGATAGGTTTCTTT 2160
ACACCAGCATGCTTACCCCTTCAACTACGGGTTTCATACCAGGCACCTCTAGAGGAGGACG 2220
GAGATCCTGTTGACGTTCTAGTTATTAGCCGGGAGCCCGTTGCTCCCGCTCGCTTATAG 2280
AGGCTGTGCCCGTGGCCGTGTAGACATGGAGGACGAGGAGGGTCCGGACAGCAAGGTTG 2340
TTGCCGTACCCAGGCCAAGCTGGACCCCTATTTCGCCAGCTATAAGGACGTTGGCGACA 2400
TACCTGATGCCCTGAAATCCAAGATAAAGCACTTCTTCGAGCACTATAAGGAGCTGGAGC 2460
CTGGAAGTGGGTAGAGTGACTGGATGGAGGCTGCTGCCGATGCGAAGGAGATTATAA 2520
GGAGGCTATAGAGAGGTATAAGGGGGCGTGATGAGGGCTTAACGGCTCACGTTTTCTGG 2580
GAGAGTGTGCGACCTTTGAGGGCGATCACCTCGCCAGCGTGCGTGTGCTTTTGTCTATG 2640
ATTATGGCTACAGTTCTTCTAGCCGCTTTCACCGCCCCACAGTCAAGCTTGGCACTGGC 2700
CGTCGTTTTACACGTCGTGACTGGGAAAACCTGGCGTTACCCAACTTAATCGCCTTGC 2760
AGCACATCCCCCTTTCCGCGAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTT 2820
CCAACAGTTGCGCAGCTGAATGGCGAATGGCGCTGATGCGGTATTTTCTCCTTACGCA 2880
TCTGTGCGGTATTTACACCGCATAAATCCCTGTTTTGGCGGATGAGAGAAGATTTTCA 2940
GCCTGATACAGATTAATCAGAACGCAAGAGCGGTCTGATAAAACAGAAATTTGCTGGCG 3000
GCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACCTCAGAAAGTGAACGCGTAGCG 3060
CCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAAGTCCAGGCATCAATAAAA 3120
CGAAAGGCTCAGTCGAAGAGCTGGGCTTTCTGTTTATCTGTTGTTGTGCGGTGAACGCT 3180
CTCCTGAGTAGGACAAATCCGCGGGAGCGGATTTGAACGTTGCGAAGCAACGGCCCGGA 3240
GGGTGGCGGGCAGGACGCGCCGCTGACGGGCTTGTCTGCTCCCGCATCGGTTACAGACAAGCT 3300
CTGACGGATGGCCTTTTTCGCTTTCTACAACTCTTCTGTCGTATATCTACAAGCCAT 3360
CCCCCAGAGATACGGTAACTAGCCTCGTTTTGTCATCAGGAAGCAGGGAATTTATGG 3420
TGCACTCTCAGTACAATCTGCTGTGATGCCGATAGTTAAGCCAGCCCCGACACCCGCCA 3480
ACACCCGCTCAGCGGCTTACGGGCTTGTCTGCTCCCGCATCGGTTACAGACAAGCT 3540
GTGACCGTCTCCGGAGCTGCATGTGTGAGAGTTTTTACCGTCATACCGAAACGCGCG 3600
AGACGAAGGGCTGATTAGAAAACTCATCGAGCATCAAATGAACTGCAATTTATTCA 3660

Figure 16 cont'd...

TATCAGGATTATCAATACCATATTTTGA AAAAGCCGTTTCTGTAATGAAGGAGAAAACT 3720
CACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTC 3780
CAACATCAATACAACCTATTAATTTCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAAT 3840
CACCATGAGTGACGACTGAATCCGGTGAGAAATGGCAAAAGNTTATGCATTTCTTTCCAGA 3900
CTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGT 3960
TATTCATTCTGATGATTCGCGCTGAGCGAGACGAAATACGCGATCGCTGTAAAAGGACAAT 4020
TACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTT 4080
CACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCNNGGGATCGCAGTGG 4140
TGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAA 4200
ATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTTGGCAACGCTACCTT 4260
TGCCATGTTTCAGAAACAACCTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCG 4320
CACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGT 4380
TGGAATTTAATCGCGGCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCC 4440
TTGTATTACTGTTTATGTAAGCAGACAGTTTATTGTTTATGATGATATATTTTATCTT 4500
GTGCAATGTAACATCAGGGCCTCGTGATACGCTATTTTATAGGTTAATGTCATGATAA 4560
TAATGGTTTCTTAGAGTGGAGTTCTGTACCCGACACCATCGAATGGTGCAAAACCTTTC 4620
GCGGTATGGCATGATAGCGCCCGAAGAGAGTCAATTGAGGGTGGTGAATGTGAAACCAG 4680
TAACGTTATACGATGTGCGCAGAGTATGCCGGTGTCTCTTATCAGACCGTTTCCCGCGTGG 4740
TGAACCGGGCCAGCCACGTTTCTGCGAAAACGCGGAAAAAGTGAAGCGGCGATGGCGG 4800
AGCTGAATTACATTTCCCAACCGGTGGCACAACAACCTGGCGGGCAACAGTCGTTGCTGA 4860
TTGGCTTGCCACCTCCAGTCTGGCCCTGCACGCGCGCTCGCAATTGTGCGGCGGATTA 4920
AATCTCGCGCCGATCAACTGGGTGCCAGCGTGGTGGTGTGATGGTAGAACGAAGCGGCG 4980
TCGAAGCCTGTAAAGCGGCGGTGCACAATCTTCTCGCGCAACGCGTCAGTGGGCTGATCA 5040
TTAACTATCCGCTGGATGACCAGGATGCCATTGCTGTGGAAGCTGCCTGCACTAATGTTT 5100
CGCGGTTATTTCTTGATGTCTCTGACCAGACACCCATCAACAGTATTATTTCTCCCATG 5160
AAGACGGTACGCGACTGGGCGTGGAGCATCTGGTCGATTGGGTACCAGCAATCGCGC 5220
TGTTAGCGGGCCATTAAAGTTCTGTCTCGGCGCGTCTGCGTCTGGCTGGCTGGCATAAAT 5280
ATCTCACTCGCAATCAAATTCAGCCGATAGCGGAACGGGAAGGCGACTGGAGTGCATGT 5340
CCCGTTTTCAACAAACCATGCAAAATGCTGAATGAGGGCATCGTTCCCACTGCGATGCTGG 5400
TTGCCAACGATCAGATGGCGCTGGGCGCAATGCGCGCCATTACCGAGTCCGGGCTGCGCG 5460
TTGGTGCGGATATCTCGGTAGTGGGATACGACGATACCGAAGACAGCTCATGTTATATCC 5520
CGCGTTAACCACCATCAAACAGGATTTTCGCTGTGGGGCAAAACAGCGTGGACCGCT 5580
TGCTGCAACTCTCTCAGGGCCAGCGGTGAAGGGCAATCAGCTGTTGCCCGTCTCACTGG 5640
TGAAAGAAAAACCCCTGGCGCCCAATACGCAAAACCGCCTCTCCCGCGCGTTGGCCG 5700
ATTCATTAATGCAGCTGGCAGCAGAGTTTCCGACTGGAAGCGGGCAGTGAGCGCAAC 5760
GCAATTAATGTAAGTTAGCTCACTCATTAGGCACCCAGGCTTTACACTTTATGCTTCCG 5820
ACCTGCAAGAACCTCAGCTCAGGTGGCACTTTTCGGGGAATGTGCGCGGAACCCCTATT 5880
TGTTTATTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCGTATAA 5940
ATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTGCGCCTT 6000
ATTCCCTTTTTCGCGCATTTTGCTTCTGTTTTGCTCAGCCAGAAACGCTGGTGAAA 6060
GTAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACATC 6105

Figure 17

Pyrostart B-Actin Taqman on human genomic



SEQUENCE LISTING

<110> The Secretary of State for Defence in Her Britannic Majesty's
Government of the United Kingdom of Great Britain and
Northern Ireland
Clark, Duncan Roy
Vincent, Suzanne P

<120> Amplification process

<130> CG/P/133/WOD

<140>

<141>

<150> GB 0110501.4

<151> 2001-04-30

<160> 26

<170> PatentIn Ver. 2.1

<210> 1

<211> 960

<212> DNA

<213> Aeropyrum pernix

<400> 1

taatcctaattcgcttttatgtggacgatcc ttcccagcaa aaccggggtt gttaacagcc 60
ttagcttttat aactcgacta gccaaactat cggttagacg ggtgcatgca atgacaggct 120
gtctgaaaat tggctcctgga gatgaggctc cagatgttgt gaatgtcgtt atagagatac 180
ctatgaacag ttctgttaag tacgagttcg acaaggaggc gtgtatttgt aagggttgata 240
ggttccttta caccagcatg gtctaccctc tcaactacgg gttcatacca ggcaactctag 300
aggaggacgg agatcctgtt gacgttctag ttattagccg ggagcccgtt gctcccggt 360
cgcttataga ggctgtgccc gtggccgtgt tagacatgga ggacgaggag ggtccggaca 420
gcaagggtgt tgccgtaccc aaggccaagc tggacccctc attcgccagc tataaggacg 480
ttggcgacat acctgatgcc ctgaaatcca agataaagca cttcttcgag cactataagg 540

agctggagcc tggaaagtgg gttagagtga ctggatggag gcctgctgcc gatgcgaagg 600
 agattataag gagggctata gagaggtata agggggcgtg atgagggcctt aacggctcac 660
 gttttctggg agagtgtcgc acctttgagg gcgatcacc tgcgcagcgt gcgtgtgctt 720
 ttgtctatga ttatggctac agttcttcta gccgctttca ccgccccac agtcaatata 780
 cttacaccta gaggttctgc gctgtatgct gtggatgtag ttgtagtaga cgccagcaca 840
 ggatctgccc tggggttctc ccggtttgtc gtatccgcct acagaggggg ggtcggggat 900
 gtgggtgtta tctactcttc gggggtctca gtatcagggt ctagtctgga aaggctgctg 960

<210> 2

<211> 207

<212> PRT

<213> Aeropyrum pernix

<400> 2

Met Trp Thr Ile Leu Pro Ser Lys Thr Gly Phe Val Asn Ser Leu Ser

1 5 10 15

Phe Ile Thr Arg Leu Ala Lys Leu Ser Val Arg Arg Val His Ala Met

20 25 30

Thr Gly Cys Leu Lys Ile Gly Pro Gly Asp Glu Ala Pro Asp Val Val

35 40 45

Asn Val Val Ile Glu Ile Pro Met Asn Ser Ser Val Lys Tyr Glu Phe

50 55 60

Asp Lys Glu Ala Cys Ile Val Lys Val Asp Arg Phe Leu Tyr Thr Ser

65 70 75 80

Met Val Tyr Pro Phe Asn Tyr Gly Phe Ile Pro Gly Thr Leu Glu Glu

85 90 95

Asp Gly Asp Pro Val Asp Val Leu Val Ile Ser Arg Glu Pro Val Ala

100 105 110

Pro Gly Ser Leu Ile Glu Ala Val Pro Val Ala Val Leu Asp Met Glu

115 120 125

3

Asp Glu Glu Gly Pro Asp Ser Lys Val Val Ala Val Pro Lys Ala Lys
 130 135 140

Leu Asp Pro Leu Phe Ala Ser Tyr Lys Asp Val Gly Asp Ile Pro Asp
 145 150 155 160

Ala Leu Lys Ser Lys Ile Lys His Phe Phe Glu His Tyr Lys Glu Leu
 165 170 175

Glu Pro Gly Lys Trp Val Arg Val Thr Gly Trp Arg Pro Ala Ala Asp
 180 185 190

Ala Lys Glu Ile Ile Arg Arg Ala Ile Glu Arg Tyr Lys Gly Ala
 195 200 205

<210> 3

<211> 173

<212> PRT

<213> Sulfolobus solfataricus

<400> 3

Met Lys Leu Ser Pro Gly Lys Asn Ala Pro Asp Val Val Asn Val Leu
 1 5 10 15

Val Glu Ile Pro Gln Gly Ser Asn Ile Lys Tyr Glu Tyr Asp Asp Glu
 20 25 30

Glu Gly Val Ile Lys Val Asp Arg Val Leu Tyr Thr Ser Met Asn Tyr
 35 40 45

Pro Phe Asn Tyr Gly Phe Ile Pro Gly Thr Leu Glu Glu Asp Gly Asp
 50 55 60

Pro Leu Asp Val Leu Val Ile Thr Asn Tyr Gln Leu Tyr Pro Gly Ser
 65 70 75 80

4

Val Ile Glu Val Arg Pro Ile Gly Ile Leu Tyr Met Lys Asp Glu Glu
85 90 95

Gly Glu Asp Ala Lys Ile Val Ala Val Pro Lys Asp Lys Thr Asp Pro
100 105 110

Ser Phe Ser Asn Ile Lys Asp Ile Asn Asp Leu Pro Gln Ala Thr Lys
115 120 125

Asn Lys Ile Val His Phe Phe Glu His Tyr Lys Glu Leu Glu Pro Gly
130 135 140

Lys Tyr Val Lys Ile Ser Gly Trp Gly Ser Ala Thr Glu Ala Lys Asn
145 150 155 160

Arg Ile Gln Leu Ala Ile Lys Arg Val Ser Gly Gly Gln
165 170

<210> 4

<211> 176

<212> PRT

<213> Escherichia coli

<400> 4

Met Ser Leu Leu Asn Gly Pro Ala Gly Lys Asp Leu Pro Glu Asp Ile
1 5 10 15

Tyr Val Val Ile Glu Ile Pro Ala Asn Ala Asp Pro Ile Lys Tyr Glu
20 25 30

Ile Asp Lys Glu Ser Gly Ala Leu Phe Val Asp Arg Phe Met Ser Thr
35 40 45

Ala Met Phe Tyr Pro Cys Asn Tyr Gly Tyr Ile Asn His Ile Leu Ser
50 55 60

5

Leu Asp Gly Asp Pro Val Asp Val Leu Val Pro Thr Pro Tyr Pro Leu
 65 70 75 80

Gln Pro Gly Ser Val Ile Arg Cys Arg Pro Val Gly Val Leu Lys Met
 85 90 95

Thr Asp Glu Ala Gly Glu Asp Ala Lys Leu Val Ala Val Pro His Ser
 100 105 110

Lys Leu Ser Lys Glu Tyr Asp His Ile Lys Asp Val Asn Asp Leu Pro
 115 120 125

Glu Leu Leu Lys Ala Gln Ile Ala His Phe Phe Glu His Tyr Lys Asp
 130 135 140

Leu Glu Lys Gly Lys Trp Val Lys Val Glu Gly Trp Glu Asn Ala Glu
 145 150 155 160

Ala Ala Lys Ala Glu Ile Val Ala Ser Phe Glu Arg Ala Lys Asn Lys
 165 170 175

<210> 5

<211> 178

<212> PRT

<213> Aquifex aeolicus

<400> 5

Met Gly Tyr Asp Gln Leu Pro Pro Gly Lys Asn Pro Pro Glu Asp Ile
 1 5 10 15

Tyr Val Val Ile Glu Ile Pro Gln Gly Ser Ala Val Lys Tyr Glu Leu
 20 25 30

Asp Lys Asp Thr Gly Val Ile Phe Val Asp Arg Phe Leu Phe Thr Ala
 35 40 45

6

Met Tyr Tyr Pro Phe Asn Tyr Gly Phe Val Pro Gln Thr Leu Ala Asp
 50 55 60

Asp Gly Asp Pro Val Asp Val Leu Val Ile Ser Arg Glu Pro Val Val
 65 70 75 80

Pro Gly Ala Val Met Arg Cys Arg Pro Ile Gly Met Leu Glu Met Arg
 85 90 95

Asp Glu Ala Gly Ile Asp Thr Lys Val Ile Ala Val Pro His Glu Lys
 100 105 110

Leu Asp Pro Ser Tyr Ser Asn Ile Lys Thr Val Asp Asn Leu Pro Glu
 115 120 125

Ile Val Arg Glu Lys Ile Lys His Phe Phe Glu His Tyr Lys Glu Leu
 130 135 140

Glu Pro Gly Lys Trp Val Lys Val Glu Asn Trp Lys Gly Leu Gln Asp
 145 150 155 160

Ala Ile Glu Glu Ile Lys Lys Gly Ile Glu Asn Tyr Lys Lys Asn Lys
 165 170 175

Glu Gly

<210> 6

<211> 178

<212> PRT

<213> *Pyrococcus horikoshii*

<400> 6

Met Asn Pro Phe His Asp Leu Glu Pro Gly Pro Asn Val Pro Glu Val
 1 5 10 15

Val Tyr Ala Leu Ile Glu Ile Pro Lys Gly Ser Arg Asn Lys Tyr Glu
 20 25 30

7

Leu Asp Lys Glu Thr Gly Leu Leu Lys Leu Asp Arg Val Leu Tyr Thr
 35 40 45

Pro Phe His Tyr Pro Val Asp Tyr Gly Ile Ile Pro Arg Thr Trp Tyr
 50 55 60

Glu Asp Gly Asp Pro Phe Asp Ile Met Val Ile Met Arg Glu Pro Thr
 65 70 75 80

Tyr Pro Leu Thr Ile Ile Glu Ala Arg Pro Ile Gly Leu Phe Lys Met
 85 90 95

Ile Asp Ser Gly Asp Lys Asp Tyr Lys Val Leu Ala Val Pro Val Glu
 100 105 110

Asp Pro Tyr Phe Lys Asp Trp Lys Asp Ile Ser Asp Val Pro Lys Ala
 115 120 125

Phe Leu Asp Glu Ile Ala His Phe Phe Lys Arg Tyr Lys Glu Leu Glu
 130 135 140

Gly Lys Glu Ile Ile Val Glu Gly Trp Glu Gly Ala Glu Ala Ala Lys
 145 150 155 160

Arg Glu Ile Leu Arg Ala Ile Glu Met Tyr Lys Glu Lys Phe Gly Lys
 165 170 175

Lys Glu

<210> 7

<211> 178

<212> PRT

<213> Pyrococcus abyssi

<400> 7

Met Asn Pro Phe His Asp Leu Glu Pro Gly Pro Asn Val Pro Glu Val
 1 5 10 15

8

Val Tyr Ala Leu Ile Glu Ile Pro Lys Gly Ser Arg Asn Lys Tyr Glu
20 25 30

Leu Asp Lys Lys Thr Gly Leu Leu Lys Leu Asp Arg Val Leu Tyr Ser
35 40 45

Pro Phe Phe Tyr Pro Val Asp Tyr Gly Ile Ile Pro Arg Thr Trp Tyr
50 55 60

Asp Asp Asp Asp Pro Phe Asp Ile Met Val Ile Met Arg Glu Pro Thr
65 70 75 80

Tyr Pro Leu Thr Ile Ile Glu Ala Arg Pro Ile Gly Leu Phe Lys Met
85 90 95

Ile Asp Ser Gly Asp Lys Asp Tyr Lys Val Leu Ala Val Pro Val Glu
100 105 110

Asp Pro Tyr Phe Lys Asp Trp Lys Asp Ile Asp Asp Val Pro Lys Ala
115 120 125

Phe Leu Asp Glu Ile Ala His Phe Phe Lys Arg Tyr Lys Glu Leu Gln
130 135 140

Gly Lys Glu Ile Ile Val Glu Gly Trp Glu Gly Ala Glu Ala Ala Lys
145 150 155 160

Arg Glu Ile Leu Arg Ala Ile Glu Leu Tyr Lys Glu Lys Phe Gly Ser
165 170 175

Lys Glu

9

<210> 8

<211> 176

<212> PRT

<213> *Thermococcus litoralis*

<400> 8

Met Asn Pro Phe His Asp Leu Glu Pro Gly Pro Glu Val Pro Glu Val

1

5

10

15

Val Tyr Ala Leu Ile Glu Ile Pro Lys Gly Ser Arg Asn Lys Tyr Glu

20

25

30

Leu Asp Lys Lys Thr Gly Leu Ile Lys Leu Asp Arg Val Leu Tyr Ser

35

40

45

Pro Phe His Tyr Pro Val Asp Tyr Gly Ile Ile Pro Gln Thr Trp Tyr

50

55

60

Asp Asp Asp Asp Pro Phe Asp Ile Met Val Ile Met Arg Glu Pro Thr

65

70

75

80

Tyr Pro Gly Val Leu Ile Glu Ala Arg Pro Ile Gly Leu Phe Lys Met

85

90

95

Ile Asp Ser Gly Asp Lys Asp Tyr Lys Val Leu Ala Val Pro Val Glu

100

105

110

Asp Pro Tyr Phe Asn Asp Trp Lys Asp Ile Ser Asp Val Pro Lys Ala

115

120

125

Phe Leu Asp Glu Ile Ala His Phe Phe Gln Arg Tyr Lys Glu Leu Gln

130

135

140

Gly Lys Glu Ile Ile Val Glu Gly Trp Glu Asn Ala Glu Lys Ala Lys

145

150

155

160

Gln Glu Ile Leu Arg Ala Ile Glu Leu Tyr Lys Glu Lys Phe Lys Lys

165

170

175

10

<210> 9

<211> 179

<212> PRT

<213> Thermoplasma acidophilum

<400> 9

Met Glu Ser Phe Tyr His Ser Val Pro Val Gly Pro Lys Pro Pro Glu

1

5

10

15

Glu Val Tyr Val Ile Val Glu Ile Pro Arg Gly Ser Arg Val Lys Tyr

20

25

30

Glu Ile Ala Lys Asp Phe Pro Gly Met Leu Val Asp Arg Val Leu Tyr

35

40

45

Ser Ser Val Val Tyr Pro Val Asp Tyr Gly Leu Ile Pro Arg Thr Leu

50

55

60

Tyr Tyr Asp Gly Asp Pro Met Asp Val Met Val Leu Ile Ser Gln Pro

65

70

75

80

Thr Phe Pro Gly Ala Ile Met Lys Val Arg Pro Ile Gly Met Met Lys

85

90

95

Met Val Asp Gln Gly Glu Thr Asp Asn Lys Ile Leu Ala Val Phe Asp

100

105

110

Lys Asp Pro Asn Val Ser Tyr Ile Lys Asp Leu Lys Asp Val Asn Ala

115

120

125

His Leu Leu Asp Glu Ile Ala Asn Phe Phe Ser Thr Tyr Lys Ile Leu

130

135

140

Glu Lys Lys Glu Thr Lys Val Leu Gly Trp Glu Gly Lys Glu Ala Ala

145

150

155

160

Leu Lys Glu Ile Glu Val Ser Ile Lys Met Tyr Glu Glu Lys Tyr Gly

165

170

175

Lys Lys Asn

<210> 10

<211> 686

<212> DNA

<213> Aeropyrum pernix

<400> 10

```

tgc atgcata tgacaggctg tctgaaaatt ggtcctggag atgaggctcc agatgttg 60
aatgtcg tta tagagatacc tatgaacagt tctgttaagt acgagttcga caaggaggcg 120
tgtattg tta aggttgatag gttcctttac accagcatgg tctacccctt caactacggg 180
tccataccag gcactctaga ggaggacgga gatcctgttg acgttctagt tattagccgg 240
gagcccg tttg ctcccggctc gcttatagag gctgtgcccg tggccgtgtt agacatggag 300
gacgaggagg gtccggacag caaggttggt gccgtaccca aggccaagct ggacccccta 360
ttcgccagct ataaggacgt tggcgacata cctgatgccc tgaaatocaa gataaagcac 420
ttcttcgagc actataagga gctggagcct ggaaagtggg ttagagtgaac tggatggagg 480
cctgctgccg atgcgaagga gattataagg agggctatag agaggtataa gggggcgtga 540
tgagggctta acggctcacc ttttctggga gagtgtcgca cctttgaggg cgatcaccct 600
cgccagcgtg cgtgtgcttt tgtctatgat tatggctaca gttcttctag ccgctttcac 660
cgccccaca gtcaagctta cactta 686

```

<210> 11

<211> 89

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Modified
polylinker sequence of pTTQ18NHK

<400> 11

```

atgcaccacc accaccacca tatgggcatg ctgaattcga gctcggtagc cggggatcct 60
ctagagtcga cctgcaggca tgcaagctt 89

```

12

<210> 12

<211> 5503

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: pTTQ18NHK
vector

<220>

<221> misc_feature

<222> (3279, 3525)

<223> n is a or g or c or t

<400> 12

gaactggatc tcaacagcgg taagatcctt gagagttttc gccccgaaga acgtttttcca 60
atgatgagca ctttttaaagt tctgctatgt ggcgcggtat tatcccgat tgacgccggg 120
caagagcaac tcggtcgcgc catacactat tctcagaatg acttggttga gtactcacca 180
gtcacagaaa agcatcttac ggatggcatg acagtaagag aattatgcag tgctgccata 240
accatgagtg ataacactgc ggccaactta cttctgacaa cgatcggagg accgaaggag 300
ctaaccgctt ttttgacaaa catgggggat catgtaactc gccttgatcg ttgggaaccg 360
gagctgaatg aagccatacc aaacgacgag cgtgacacca cgatgcctgt agcaatggca 420
acaacgttgc gcaaactatt aactggcgaa ctacttactc tagctteccg gcaacaatta 480
atagactgga tggaggcgga taaagttgca ggaccacttc tgcgctcggc ccttcgggct 540
ggctggttta ttgctgataa atctggagcc ggtgagcgtg ggtctcggg tatcattgca 600
gcactggggc cagatggtaa gccctcccgat atcgtagtta tctacacgac ggggagtcag 660
gcaactatgg atgaacgaaa tagacagatc gctgagatag gtgcctcact gattaagcat 720
tggttaactgt cagaccaagt ttactcatat atactttaga ttgatttaaa acttcaattt 780
taattttaaaa ggatctaggt gaagatcctt tttgataatc tcatgaccaa aatcccttaa 840
cgtgagtttt cgttccactg agcgtcagac cccgtagaaa agatcaaagg atcttcttga 900
gatccttttt ttctgcgcgt aatctgctgc ttgcaaacia aaaaaccacc gctaccagcg 960
gtggtttgtt tgccggatca agagctacca actctttttc cgaaggtaac tggtttcagc 1020
agagcgcaga taccaaatac tgtccttcta gtgtagccgt agttaggcca ccacttcaag 1080
aactctgtag caccgcctac atacctcgct ctgctaatac tgttaccagt ggtgctgcc 1140
agtggcgata agtcgtgtct taccgggttg gactcaagac gatagttacc ggataaggcg 1200
cagcggtcgg gctgaacggg gggttcgtgc acacagccca gcttgagcg aacgacctac 1260
accgaactga gatacctaca gcgtgagcat tgagaaagcg ccacgcttcc cgaagggaga 1320
aaggcggaca ggtatccggt aagcggcagg gtcggaacag gagagcgac gagggagctt 1380

ccaggggaa acgcctggta tctttatagt cctgtcgggt ttcgccacct ctgacttgag 1440
cgtcgatttt tgtgatgtc gtcagggggg cggagcctat ggaaaaacgc cagcaacgcg 1500
gcctttttac ggttcctggc cttttgctgg cttttgctc acatgttctt tcctgcgtta 1560
tccctgatt ctgtggataa ccgtattacc gcctttgagt gagctgatac cgctcgccgc 1620
agccgaacga ccgagcgcag cgagtcagtg agcgaggaag cggaagagcg cccaatacgc 1680
aaaccgcctc tccccgcgcg ttggccgatt cattaatgca gaattaatc tcatgtttga 1740
cagcttatca tcgactgcac ggtgcaccaa tgcttctggc gtcaggcagc catcggaagc 1800
tgtggtatgg ctgtgcaggc cgtaaatcac tgcataatc gtgtcgtca aggcgcactc 1860
ccgttctgga taatgttttt tgcgccgaca tcataacggt tctggcaaat attctgaaat 1920
gagctgttga caattaatca tcggctcgta taatgtgtgg aattgtgagc ggataacaat 1980
ttcacacagg aaacacatat atgcaccacc accaccacca tatgggcatg ctgaattcga 2040
gctcgttacc cggggatcct ctagagtoga cctgcaggca tgcaagcttg gactggccg 2100
tcgttttaca acgtcgtgac tgggaaaacc ctggcggttac ccaacttaat cgccttgag 2160
cacatcccc tttcgccagc tggcgtaata gcgaagagc ccgcaccgat cgccttccc 2220
aacagttgcg cagcctgaat ggcgaaatggc gcctgatgcg gtattttctc cttacgcac 2280
tgtgcggtat ttcacaccgc ataaattccc tgttttggcg gatgagagaa gattttcagc 2340
ctgatacaga ttaaatacaga acgcagaagc ggtctgataa aacagaatct gcctggcggc 2400
agtagcgcgg tgggtcccacc tgaccccatg ccgaactcag aagtgaacgc ccgtagcgcc 2460
gatggtagtg tggggtctcc ccatgcgaga gtagggaact gccaggcatc aaataaaacg 2520
aaaggctcag tcgaaagact gggcctttcg ttttatctgt tgtttgtcgg tgaacgctct 2580
cctgagtagg acaaatccgc cgggagcgga tttgaacgtt gcgaagcaac ggcccgagg 2640
gtggcgggca ggacgccgc cataaactgc caggcatcaa attaagcaga aggccatcct 2700
gacggatggc ctttttgcgt ttctacaaac tcttctgtc gtcatactca caagccatcc 2760
ccccacagat acggtaaaact agcctcgttt ttgcatcagg aaagcaggga atttatggtg 2820
cactctcagt acaatctgct ctgatgccgc atagttaagc cagccccgac acccgccaac 2880
acccgctgac gcgcctgac gggcttgtct gctcccgga tccgcttaca gacaagctgt 2940
gaccgtctcc gggagctgca tgtgtcagag gttttcaccg tcatcaccga aacgcgcgag 3000
acgaaaggc ctgattagaa aaactcatcg agcatcaaat gaaactgcaa tttattcata 3060
tcaggattat caataccata tttttgaaa agccgtttct gtaatgaagg agaaaactca 3120
ccgaggcagt tccataggat ggcaagatcc tggatatcgt ctgcgattcc gactcgtcca 3180
acatcaatac aacctattaa tttcccctcg tcaaaaataa ggttatcaag tgagaaatca 3240
ccatgagtga cgactgaatc cggtgagaat ggcaaaagnt tatgcatttc tttccagact 3300
tgttcaacag gccagccatt acgctcgtca tcaaaatcac tcgcatcaac caaacgtta 3360
ttcattcgtg attgcgctg agcgagacga aatacgcgat cgctgttaaa aggacaatta 3420
caaacaggaa tcgaatgcaa ccggcgagc aacactgccg gcgcatcaac aatattttca 3480
cctgaatcag gatattcttc taatacctgg aatgctgttt tccnnggat cgcagtgggtg 3540
agtaaccatg catcatcagg agtacggata aaatgcttga tggtcggaag aggcataaat 3600
tccgtcagcc agtttagtct gaccatctca tctgtaacat cattggcaac gctacctttg 3660

ccatgtttca gaaacaactc tggcgcatcg ggcttcccat acaatcgata gattgtcgca 3720
 cctgattgcc cgacattatc gcgagcccat ttatacccat ataaatcagc atccatggtg 3780
 gaatttaatc ggggcctcga gcaagacgtt tcccgttgaa tatggctcat aacacccctt 3840
 gtattactgt ttatgtaagc agacagtttt attgttcacg atgatataatt tttatcttgt 3900
 gcaatgtaac atcagggcct cgtgatacgc ctatTTTTat aggttaatgt catgataata 3960
 atggtttctt agacgtgagg ttctgtaccc gacacccatcg aatggtgcaa aacctttcgc 4020
 ggtatggcat gatagcgccc ggaagagagt caattcaggg tggatgaatgt gaaaccagta 4080
 acgttatacag atgtcgcaga gtatgccggt gtctcttata agaccgtttc ccgctggtg 4140
 aaccaggcca gccacgtttc tgcgaaaacg cgggaaaaag tggaaagcggc gatggcggag 4200
 ctgaattaca ttcccaaccg cgtggcacia caactggcgg gcaaacagtc gttgctgatt 4260
 ggcgttgcca cctccagtct ggccctgcac gcgcctcgc aaattgtcgc ggcgattaaa 4320
 tctcgcgcgc atcaactggg tgcagcgtg gtggtgtcga tggtagaacg aagcggcgtc 4380
 gaagcctgta aagcggcgtt gcacaatctt ctgcgcgaac gcgtcagtgg gctgatcatt 4440
 aactatccgc tggatgacca ggatgccatt gctgtggaag ctgcctgcac taatgttccg 4500
 gcgttatttc ttgatgtctc tgaccagaca cccatcaaca gtattatttt ctcccatgaa 4560
 gacggtagcgc gactgggcgt ggagcatctg gtgcgattgg gtcaccagca aatcgcgctg 4620
 ttagcgggcc .cattaagttc tgtctcggcg cgtctgcgtc tggctggctg gcataaatat 4680
 ctcaactcga atcaaattca gccgatagcg gaaagggaag gcgactggag tgccatgtcc 4740
 ggttttcaac aaaccatgca aatgctgaat gagggcatcg ttccactgc gatgctggtt 4800
 gccaacgac agatggcgct gggcgcaatg cgcgccatta ccgagtcgg gctgcgcgtt 4860
 ggtgcggata tctcggtagt gggatacgac gataccgaag acagctcatg ttatatcccg 4920
 ccgttaacca ccatcaaaca ggattttcgc ctgctggggc aaaccagcgt ggaccgcttg 4980
 ctgcaactct ctcagggccca ggcggtgaag ggcaatcagc tgttgcccg ctcactggtg 5040
 aaaagaaaaa ccaccctggc gcccaatacg caaacgcct ctccccgcgc gttggccgat 5100
 tcattaatgc agctggcacg acaggtttcc cgactggaaa gcgggcagtg agcgcaacgc 5160
 aattaatgta agttagctca ctcattaggc accccaggct ttacacttta tgcttccgac 5220
 ctgcaagaac ctcacgtcag gtggcacttt tcggggaaat gtgcgcggaa cccctatttg 5280
 tttatttttc taaatacatt caaatatgta tccgctcatg agacaataac cctgataaat 5340
 gcttcaataa tattgaaaaa ggaagagtat gagtattcaa catttcogtg tcgcccttat 5400
 tccctttttt gcggcatttt gccttcctgt ttttgcac ccagaaacgc tggtgaaagt 5460
 aaaagatgct gaagatcagt tgggtgcacg agtgggttac atc 5503

15

<210> 13

<211> 6105

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: pTTQ18NHK
vector including the PPase sequence

<220>

<221> misc_feature

<222> (3881, 4127)

<223> n is a or g or c or t

<400> 13

gaactggatc tcaacagcgg taagatcctt gagagttttc gccccgaaga acgtttttcca 60
atgatgagca ctttttaaagt tctgctatgt ggcgcgggtat tatcccgat tgacgccggg 120
caagagcaac tcggtcgccg catacactat tctcagaatg acttggttga gtactcacca 180
gtcacagaaa agcatcttac ggatggcatg acagtaagag aattatgcag tgctgccata 240
accatgagtg ataacactgc ggccaactta cttctgacaa cgatcggagg accgaaggag 300
ctaaccgctt ttttgacaaa catgggggat catgtaactc gccttgatcg ttgggaaccg 360
gagctgaatg aagccatacc aaacgacgag cgtgacacca cgatgcctgt agcaatggca 420
acaacgttgc gcaaactatt aactggcgaa ctacttactc tagcttccc gcaacaatta 480
atagactgga tggaggcgga taaagttgca ggaccacttc tgcgctcggc ccttccggct 540
ggctggttta ttgctgataa atctggagcc ggtgagcgtg ggtctcggg tatcattgca 600
gcactggggc cagatggtaa gccctccgt atcgtagtta tctacacgac ggggagtcag 660
gcaactatgg atgaacgaaa tagacagatc gctgagatag gtgcctcact gattaagcat 720
tggttaactgt cagaccaagt ttactcatat atactttaga ttgatttaaa acttcatttt 780
taatttaaaa ggatctaggt gaagatcctt tttgataatc tcatgaccaa aatcccttaa 840
cgtgagtttt cgttccactg agcgtcagac ccgtagaaa agatcaaagg atcttcttga 900
gatccttttt ttctgcgcgt aatctgctgc ttgcaaacia aaaaaccacc gctaccagcg 960
gtgggtttgt tgccggatca agagctacca actctttttc cgaaggtaac tggtttcagc 1020
agagcgcaga taccaaatac tgtccttcta gtgtagccgt agttaggcca ccacttcaag 1080
aactctgtag caccgcctac atacctcgct ctgctaatac tgttaccagt ggtgctgcc 1140
agtggcgata agtcgtgtct taccgggttg gactcaagac gatagttacc ggataaggcg 1200
cagcggtcgg gctgaacggg gggttcgtgc acacagccca gcttgagcg aacgacctac 1260
accgaactga gatacctaca gcgtgagcat tgagaaagcg ccacgcttcc cgaagggaga 1320
aaggcggaca ggtatccggt aagcggcagg gtcggaacag gagagcgcac gagggagctt 1380

ccagggggaa acgcctggta tctttatagt cctgtcgggt ttcgccacct ctgacttgag 1440
cgtcgatttt tgtgatgctc gtcagggggg cgagagcctat ggaaaaacgc cagcaacgcg 1500
gcctttttac ggttcctggc cttttgctgg ccttttgctc acatgttctt tcctgcgtta 1560
tcccctgatt ctgtggataa ccgtattacc gcctttgagt gagctgatac cgctcgccgc 1620
agccgaacga ccgagcgag cgagtcagtg agcgaggaag cggaagagcg cccaatacgc 1680
aaaccgcctc tcccgcgcg ttggccgatt cattaatgca gaattaattc tcatgtttga 1740
cagcttatca tcgactgcac ggtgcaccaa tgcttctggc gtcaggcagc catcggaagc 1800
tgtggtatgg ctgtgcaggt cgtaaatac tgacataatc gtgtcgctca aggcgcactc 1860
ccgttctgga taatgttttt tgcgcgcaca tcataacggt tctggcaaatt attctgaaat 1920
gagctgttga caattaatca tcggctcgta taatgtgtgg aattgtgagc ggataacaat 1980
ttcacacagg aaacacatat atgcaccacc accaccacca tatgacaggc tgtctgaaaa 2040
ttggtcctgg agatgaggct ccagatgttg tgaatgtcgt tatagagata cctatgaaca 2100
gttctgttaa gtacgagttc gacaaggagg cgtgtattgt taaggttgat aggttccttt 2160
acaccagcat ggtctacccc ttcaactacg ggttcatacc aggcactcta gaggaggacg 2220
gagatcctgt tgacgttcta gttattagcc gggagcccg tgcctccggc tcgcttatag 2280
aggctgtgcc cgtggccgtg ttagacatgg aggcagagga gggccggac agcaagggtg 2340
ttgccgtacc caaggccaag ctggaccccc tattcgccag ctataaggac gttggcgaca 2400
tacctgatgc cctgaaatcc aagataaagc acttcttcga gcactataag gagctggagc 2460
ctggaaagtg ggttagagtg actggatgga ggccgtctgc cgatgcgaag gagattataa 2520
ggagggctat agagaggat aagggggcgt gatgagggt taacggctca cgttttctgg 2580
gagagtgtcg cacctttgag ggcgatcacc ctgcgcagcg tgcgtgtgct tttgtctatg 2640
attatggcta cagttcttct agccgctttc accgccccca cagtcaagct tggcactggc 2700
cgtcgtttta caacgtcgtg actgggaaaa ccctggcggt acccaactta atcgccctgc 2760
agcacatccc cctttcgcca gctggcgtaa tagcgaagag gccgcgaccg atcgcccttc 2820
ccaacagttg cgcagcctga atggcgaaat gcgcctgatg cggatatttc tccttacgca 2880
tctgtgcggt atttcacacc gcataaattc cctgttttg cggatgagag aagattttca 2940
gcctgataca gattaaatca gaacgcagaa gcggtctgat aaaacagaat ttgcctggcg 3000
gcagtagcgc ggtggtccca cctgacccca tgccgaactc agaagtgaag cgccgtagcg 3060
ccgatggtag tgtggggtct ccccatgcga gagtagggaa ctgccaggca tcaaataaaa 3120
cgaaaggctc agtcgaaaga ctgggccttt cgttttatct gttgtttgtc ggtgaacgct 3180
ctcctgagta ggacaaatcc gccgggagcg gatttgaaag ttgcgaagca acggcccgga 3240
gggtggcggg caggacgccc gccataaact gccaggcatc aaattaagca gaaggccatc 3300
ctgacggatg gcctttttgc gtttctacaa actcttctg tcgtcatatc tacaagccat 3360
ccccccacag atacggtaaa ctagcctcgt ttttgcatca ggaaagcagg gaatttatgg 3420
tgcaactctc gtacaatctg ctctgatgcc gcatagttaa gccagccccg acaccgcca 3480
acaccgctg acgcgcctg acgggcttgt ctgctcccg catccgctta cagacaagct 3540
gtgaccgtct ccgggagctg catgtgtcag aggtttttac cgtcatcacc gaaacgcgcg 3600
agacgaaagg gcctgattag aaaaactcat cgagcatcaa atgaaactgc aattttattca 3660

tatcaggatt atcaatacca tttttttgaa aaagccgttt ctgtaatgaa ggagaaaact 3720
caccgaggca gttccatagg atggcaagat cctgggtatcg gtctgcgatt cggactcgtc 3780
caacatcaat acaacctatt aattttccct cgtcaaaaat aaggttatca agtgagaaat 3840
caccatgagt gacgactgaa tccggtgaga atggcaaaag nttatgcatt tctttccaga 3900
cttgttcaac aggccagcca ttacgctcgt catcaaaatc actcgcatca accaaaccgt 3960
tattcattcg tgattgcgcc tgagcgagac gaaatacgcg atcgctgtta aaaggacaat 4020
tacaaacagg aatcgaatgc aaccggcgca ggaacactgc cagcgcatca acaatatttt 4080
cacctgaatc aggatattct tctaatacct ggaatgctgt tttccnggg atcgcagtgg 4140
tgagtaacca tgcattcatca ggagtacgga taaaatgctt gatggtcgga agaggcataa 4200
attccgtcag ccagtttagt ctgaccatct catctgtaac atcattggca acgctacctt 4260
tgccatgttt cagaaacaac tctggcgcat cgggcttccc atacaatcga tagattgtcg 4320
cacctgattg ccgacatta tccgagagcc atttataccc atataaatca gcatccatgt 4380
tggaatttaa tccgggcctc gagcaagacg tttcccggtt aatatggctc ataacacccc 4440
ttgtattact gtttatgtaa gcagacagtt ttattgttca tgatgatata tttttatctt 4500
gtgcaatgta acatcagggc ctcgatgatac gcctattttt ataggttaat gtcattgataa 4560
taatggtttc ttagacgtga ggttctgtac ccgacaccat cgaatgggtgc aaaacctttc 4620
gcggtatggc atgatagcgc ccggaagaga gtcaattcag ggtgggtgaat gtgaaaccag 4680
taacgttata cgatgtcgca gagtatgccg gtgtctctta tcagaccgtt tcccgcggtg 4740
tgaaccaggc cagccacgtt tctgcgaaaa cgcgggaaaa agtgggaagc gcgatggcg 4800
agctgaatta cattcccaac cgcgtggcac aacaactggc gggcaaacag tcggttgctga 4860
ttggcggtgc cacctccagt ctggccctgc acgcgccgtc gcaaattgtc gcggcgatta 4920
aatctcgcgc cgatcaactg ggtgccagcg tgggtgggtgc gatggtagaa cgaagcggcg 4980
tcgaagcctg taaagcggcg gtgcacaatc ttctcgcgca acgcgtcagt gggtgatca 5040
ttaactatcc gctggatgac caggatgcc a ttgctgtgga agctgcctgc actaatgttc 5100
cggcggttatt tcttgatgtc tctgaccaga caccatcaa cagtattatt ttctcccatg 5160
aagacgggtac gcgactgggc gtggagcatc tggtcgcatt gggtcaccag caaatcgcgc 5220
tgtagcggg ccattaaagt tctgtctcgg cgcgtctcgc tctggctggc tggcataaat 5280
atctcactcg caatcaaatt cagccgatag cggaaacggga aggcgactgg agtgccatgt 5340
ccggttttca acaaaccatg caaatgctga atgagggcat cgttcccact gcgatgctgg 5400
ttgccaacga tcagatggcg ctgggcgcaa tgcgcgccat taccgagtcc gggctgcgcg 5460
ttggtgcgga tatctcggtg gtgggatacg acgataccga agacagctca tgttatatcc 5520
cgccgttaac caccatcaaa caggattttc gcctgctggg gcaaaccagc gtggaccgct 5580
tgctgcaact ctctcagggc caggcgggtga agggcaatca gctgttgccc gtctcactgg 5640
tgaaaagaaa aaccacctg gcgccaata cgcaaaccgc ctctccccgc gcgttggccg 5700
attcattaat gcagctggca cgacaggttt cccgactgga aagcgggcag tgagcgcaac 5760
gcaattaatg taagttagct cactcattag gcacccagc ctttacactt tatgcttccg 5820
acctgcaaga acctcacgtc aggtggcact tttcggggaa atgtgcgcgg aacctctatt 5880
tgtttatttt tctaaatata ttcaaatatg tatccgctca tgagacaata acctgataa 5940

18

atgcttcaat aatattgaaa aaggaagagt atgagtattc aacatttccg tgtcgccctt 6000
attccctttt ttgcggcatt ttgccttcct gtttttgctc acccagaaac gctgggtgaaa 6060
gtaaaagatg ctgaagatca gttgggtgca cgagtgggtt acatc 6105

<210> 14

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 14

gatgagttcg tgtccgtaca actgg 25

<210> 15

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 15

ggttatcgaa atcagccaca gcgcc 25

<210> 16

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

19

<400> 16

gcaacgcccc tcactataaa

20

<210> 17

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 17

gcaccccgcc cttgaagtcc

20

<210> 18

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 18

tgcattcata tgacaggctg tctgaaaatt g

31

<210> 19

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 19

taagtgtgaa cttgactgtg ggggcggtga aag

33

20

<210> 20

<400> 20

000

<210> 21

<400> 21

000

<210> 22

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 22

gactcgtcat actcctgctt gct

23

<210> 23

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 23

cattgccgac aggatgcaga a

21

21

<210> 24

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Probe

<400> 24

atccacatct gctggaaggt ggacagt

27

<210> 25

<211> 176

<212> PRT

<213> Aeropyrum pernix

<400> 25

Met Thr Gly Cys Leu Lys Ile Gly Pro Gly Asp Glu Ala Pro Asp Val

1

5

10

15

Val Asn Val Val Ile Glu Ile Pro Met Asn Ser Ser Val Lys Tyr Glu

20

25

30

Phe Asp Lys Glu Ala Cys Ile Val Lys Val Asp Arg Phe Leu Tyr Thr

35

40

45

Ser Met Val Tyr Pro Phe Asn Tyr Gly Phe Ile Pro Gly Thr Leu Glu

50

55

60

Glu Asp Gly Asp Pro Val Asp Val Leu Val Ile Ser Arg Glu Pro Val

65

70

75

80

Ala Pro Gly Ser Leu Ile Glu Ala Val Pro Val Ala Val Leu Asp Met

85

90

95

Glu Asp Glu Glu Gly Pro Asp Ser Lys Val Val Ala Val Pro Lys Ala

100

105

110

22

Lys Leu Asp Pro Leu Phe Ala Ser Tyr Lys Asp Val Gly Asp Ile Pro
115 120 125

Asp Ala Leu Lys Ser Lys Ile Lys His Phe Phe Glu His Tyr Lys Glu
130 135 140

Leu Glu Pro Gly Lys Trp Val Arg Val Thr Gly Trp Arg Pro Ala Ala
145 150 155 160

Asp Ala Lys Glu Ile Ile Arg Arg Ala Ile Glu Arg Tyr Lys Gly Ala
165 170 175

<210> 26

<211> 531

<212> DNA

<213> Aeropyrum pernix

<400> 26

atgacaggct gtctgaaaat tggctcctgga gatgaggctc cagatgttgt gaatgtcggt 60
atagagatac ctatgaacag ttctgttaag tacgagttcg acaaggaggc gtgtattgtt 120
aaggttgata gggtccttta caccagcatg gtctaccctt tcaactacgg gttcatacca 180
ggcactctag aggaggacgg agatcctggt gacgttctag ttattagccg ggagcccggt 240
gctcccggtc cgcttataga ggctgtgccc gtggccgtgt tagacatgga ggacgaggag 300
gttccggaca gcaagggtgt tgccgtaccc aaggccaagc tggacccctt attcgccagc 360
tataaggacg ttggcgacat acctgatgcc ctgaaatcca agataaagca cttcttcgag 420
cactataagg agctggagcc tggaaagtgg gttagagtga ctggatggag gcctgctgcc 480
gatgcgaagg agattataag gagggctata gagaggtata agggggcgtg a 531

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 November 2002 (07.11.2002)

PCT

(10) International Publication Number
WO 02/088387 A3

- (51) International Patent Classification⁷: **C12Q 1/68**
- (21) International Application Number: **PCT/GB02/01861**
- (22) International Filing Date: **22 April 2002 (22.04.2002)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
0110501.4 **30 April 2001 (30.04.2001)** **GB**
- (71) Applicant (for all designated States except US): **THE SECRETARY OF STATE FOR DEFENCE [GB/GB]; DSTL, Porton Down, Salisbury, Wiltshire SP4 0JQ (GB).**
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **CLARK, Duncan, Roy [GB/GB]; GeneSys Limited, Suite 5, St. Albans House, 40 Lynchford Road, Farnborough, Hants GU14 6EF (GB). VINCENT, Suzanne, Patricia [GB/GB]; GeneSys Limited, Suite 5, St Albans House, 40 Lynchford Road, Farnborough, Hants GU14 6EF (GB).**
- (74) Agent: **GREAVES, Carol, Pauline; Greaves Brewster, Indigo House, Cheddar Business Park, Wedmore Road, Cheddar Somerset BS27 3EB (GB).**
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.**
- (84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**
- Published:
— with international search report
- (88) Date of publication of the international search report:
11 December 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **AMPLIFICATION PROCESS**

(57) Abstract: A method for conducting a nucleic acid amplification reaction, said method comprising forming an amplification reaction mixture in the presence of sufficient of a pyrophosphate salt to prevent primer extension taking place, digesting said pyrophosphate salt with a pyrophosphatase enzyme (PPase), and subjecting said reaction mixture to conditions such that an amplification reaction may proceed. This can be used as a "hot start" amplification. Particular novel pyrophosphatase enzymes for use in the method are also described and claimed.

WO 02/088387 A3

INTERNATIONAL SEARCH REPORT

PCT/GB 02/01861

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 05797 A (KORPELA TIMO ;SEVERIN EVGENII (RU); KISELEV VSEVOLOD (RU)) 17 March 1994 (1994-03-17) abstract page 1, paragraph 1 page 5, paragraph 1 - paragraph 2 example 7 claims 1-3,11	1-3,8, 14-16, 19,20
X	EP 0 763 599 A (HOFFMANN LA ROCHE) 19 March 1997 (1997-03-19) abstract claim 11	1,19
X	WO 98 22615 A (LIFE TECHNOLOGIES INC) 28 May 1998 (1998-05-28) abstract	1,19
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

24 March 2003

Date of mailing of the international search report

17/09/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Weijland, A

INTERNATIONAL SEARCH REPORT

PCT/GB 02/01861

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE NCBI 'Online! 30 May 2000 (2000-05-30) Database accession no. Q9YBA5 XP002234664 ---	23
X	DATABASE NCBI 'Online! Database accession no. ap000062.1, 23 June 1999 (1999-06-23) XP002234665 -----	24

INTERNATIONAL SEARCH REPORT

PCT/GB 02/01861

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 26
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Claims Nos.: 26

Present claim 26 relates to an extremely large number of possible methods. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds/products/apparatus/methods claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds/products/apparatus/methods

*****'indicate precisely what has been covered by the search e.g those compounds etc. prepared in the examples and closely related homologous compounds etc./those compounds etc. mentioned in the description at pages YY/given in Formula 1, where A = C4, B = C6 etc.!*****

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

PCT/GB 02/01861

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9405797	A	17-03-1994	FI	923911 A	02-03-1994
			AU	4960893 A	29-03-1994
			WO	9405797 A1	17-03-1994
EP 0763599	A	19-03-1997	US	5665551 A	09-09-1997
			CA	2185362 A1	14-03-1997
			EP	0763599 A2	19-03-1997
			JP	2863738 B2	03-03-1999
			JP	9140387 A	03-06-1997
WO 9822615	A	28-05-1998	US	6291164 B1	18-09-2001
			AU	7302198 A	10-06-1998
			WO	9822615 A1	28-05-1998
			US	2001055792 A1	27-12-2001